

STN Columbus

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5	AUG 24	CA/Cplus enhanced with legal status information for U.S. patents
NEWS 6	SEP 09	50 Million+ Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7	SEP 11	WPIDS, WINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10	NOV 23	Addition of SCAN format to selected STN databases
NEWS 11	NOV 23	Annual Reload of IFI Databases
NEWS 12	DEC 01	FRFULL Content and Search Enhancements
NEWS 13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/Cplus
NEWS 18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 19	JAN 25	Annual Reload of MEDLINE database
NEWS 20	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 21	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 22	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 23	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 24	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:43:35 ON 17 FEB 2010

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY TOTAL
0.22 SESSION 0.22

FILE 'REGISTRY' ENTERED AT 18:43:42 ON 17 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 FEB 2010 HIGHEST RN 1206670-64-5
DICTIONARY FILE UPDATES: 16 FEB 2010 HIGHEST RN 1206670-64-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/reg/stndoc/properties.html>


=> e clotrimazole/cn
E1 1 CLOTRICILLIN/CN
E2 1 CLOTRIDE/CN
E3 1 --> CLOTRIMAZOLE/CN
E4 1 CLOTRIMAZOLE HYDROCHLORIDE/CN
E5 1 CLOTRIMAZOLE NITRATE/CN
E6 1 CLOTRIMAZOLE-BENZOIC ACID MIXT./CN
E7 1 CLOTRIMAZOLE-SILVER NITRATE MIXT./CN
E8 1 CLOTRIMAZOLE-SILVER SULFADIAZINE MIXT./CN
E9 1 CLOTROX/CN
E10 1 CLOTTABLE PROTEIN (MARSUPENAEUS JAPONICUS)/CN
E11 1 CLOTTING PROTEIN (PACIFASTACUS LENIUSCULUS PRECURSOR)/CN
E12 1 CLOTURIN/CN

=> s e3
L1 1 CLOTRIMAZOLE/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN 23593-75-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[(2-chlorophenyl)diphenylmethyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Imidazole, 1-(o-chloro- α , α -diphenylbenzyl)- (8CI)
OTHER NAMES:
CN 1-(o-Chlorophenyl)diphenylmethylimidazole
CN 1-(o-Chlorotriptyl)imidazole
CN 1-[(2-Chlorophenyl)diphenylmethyl]-1H-imidazole
CN BAY 5097
CN BAY 5907
CN BAY-B 5097
CN Canesten
CN Canifug
CN Clotrimazole
CN Desamix F
CN Diphenyl(2-chlorophenyl)(1-imidazolyl)methane
CN Empecid
CN Femcare
CN Gyne-Lotrimin
CN Gyne-Lotrimin 7
CN Locasten

CN Lotrimin
 CN Lotrimin AF Cream
 CN Lotrimin AF Solution
 CN Lotrimin Jock-Itch Cream
 CN Lotrimin Jock-Itch Lotion
 CN Monobaycuten
 CN Mycelex
 CN Mycelex 7
 CN Mycelex G
 CN Mycelex OTC
 CN Mycelex Troche
 CN Mycofug
 CN Mycosporin
 CN NSC 257473
 CN Pedisafe
 CN Plimycol
 CN Rimazole
 CN Tibatin
 CN Trimysten
 CN Veltriam
 DR 117829-71-7
 MF C22 H17 Cl N2
 CI CON
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOSIS, BIOTECHNO, CA, CABAB, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,
 CIN, CSChem, CSNB, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB,
 IMSDRUGNEWS, IMPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
 MSDS-OHS, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN,
 USPAT2, USPATFULL, USPATOLD, VETU
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2647 REFERENCES IN FILE CA (1907 TO DATE)
 53 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2655 REFERENCES IN FILE CAPLUS (1907 TO DATE)


```

-> e tram 34/cn
E1      1      TRAM 3/CN
E2      1      TRAM 30/CN
E3      1 --> TRAM 34/CN
E4      1      TRAM 39/CN
E5      1      TRAM DOMAIN PROTEIN (HALOARCULA MARISMORTUI STRAIN ATCC 4304
         9)/CN
E6      1      TRAM DOMAIN PROTEIN (WOLBACHIA PIPPENTIS STRAIN WMEL)/CN
E7      1      TRAM FAMILY PROTEIN (LEPTOSPIRA INTERROGANS ICTEROHAEMORRHAG
         IAE STRAIN 56601 GENE LA0250)/CN
E8      1      TRAM PROTEIN (HUMAN CELL LINE HELA GENE TRAM)/CN
E9      1      TRAM PROTEIN (LEGIONELLA PNEUMOPHILA STRAIN CORBY GENE TRAM)
         /CN
E10     1      TRAM PROTEIN (PLASMID PB10 GENE TRAM)/CN
E11     1      TRAM PROTEIN (PLASMID PB8 GENE TRAM)/CN
E12     1      TRAM PROTEIN (PLASMID PDC3000A GENE TRAM-2)/CN

=> s e3
L2      1 "TRAM 34"/CN
  
```

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN 289905-88-0 REGISTRY
ED Entered STN: 21 Sep 2000
CN 1H-Pyrazole, 1-[(2-chlorophenyl)diphenylmethyl]- (CA INDEX NAME)
OTHER NAMES:
CN TRAM 34
MF C22 H17 Cl N2
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

33 REFERENCES IN FILE CA (1907 TO DATE)
33 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file ca	COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST		16.18	16.40

FILE 'CA' ENTERED AT 18:45:01 ON 17 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Feb 2010 VOL 152 ISS 8
FILE LAST UPDATED: 11 Feb 2010 (20100211/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CA now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12
L3 33 L2

=> d 1-33

L3 ANSWER 1 OF 33 CA COPYRIGHT 2010 ACS on STN
Full Text
AN 151:485058 CA

TI Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels
AU Grgic, Ivica; Kiss, Eva; Kaistha, Brehesh P.; Busch, Christoph; Kloss, Michael; Sautter, Julia; Muller, Anja; Kaistha, Anuradha; Schmidt, Claudia; Raman, Girija; Wulff, Heike; Strutz, Frank; Grone, Hermann-Josef; Kohler, Ralf; Hoyer, Joachim
CS Department of Internal Medicine and Nephrology, Philipps-University, Marburg, 35033, Germany
SO Proceedings of the National Academy of Sciences of the United States of America (2009), 106(34), 14518-14523, S14518/1-S14518/9
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 151:504 CA
TI Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants
AU Pegoraro, Stefano; Lang, Martin; Dreker, Tobias; Kraus, Juergen; Hamm, Svetlana; Meere, Cathal; Feurle, Julianne; Tasler, Stefan; Pruetting, Sylvia; Kuras, Zerrin; Visan, Violeta; Grissmer, Stephan
CS 4SC AG, Planegg-Martinsried, 82152, Germany
SO Bioorganic & Medicinal Chemistry Letters (2009), 19(8), 2299-2304
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 150:480884 CA
TI System for treatment and imaging using ultrasonic energy and microbubbles
IN Hossack, John A.; Wanhoff, Brian R.; Klibanov, Alexander L.
PA University of Virginia Patent Foundation, USA
SO PCT Int. Appl., 82pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009055720	A1	20090430	WO 2008-US81189	20081024
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2007-632P	P	20071026		
US 2008-99025P	P	20080922		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 150:280723 CA
TI KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease
AU Albaqumi, Mamdouh; Srivastava, Shekhar; Li, Zhai; Zhordova, Olga; Wulff, Heike; Itani, Omar; Wallace, Darren P.; Skolnik, Edward Y.

CS Division of Nephrology, New York University School of Medicine, New York,
NY, 10016, USA
SO Kidney International (2008), 74(6), 740-749
CODEN: KDYIA5; ISSN: 0085-2538
PB Nature Publishing Group
DT Journal
LA English
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 149:530308 CA
TI The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherosclerosis in mice and humans
AU Toyama, Kazuyoshi; Wulff, Heike; Chandy, K. George; Azam, Philippe; Raman, Girija; Saito, Takashi; Fujiwara, Yoshimasa; Mattson, David L.; Das, Satarupa; Melvin, James E.; Pratt, Phillip F.; Hatoum, Ossama A.; Guterman, David D.; Harder, David R.; Miura, Hiroto
CS Department of Medicine and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA
SO Journal of Clinical Investigation (2008), 118(9), 3025-3037
CODEN: JCINAO; ISSN: 0021-9738
PB American Society for Clinical Investigation
DT Journal
LA English
OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 149:486453 CA
TI Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis
AU Tharp, D. L.; Wamhoff, B. R.; Wulff, H.; Raman, G.; Cheong, A.; Bowles, D. K.
CS Department of Biomedical Sciences, and Research Angiography Core, University of Missouri, Columbia, MO, USA
SO Arteriosclerosis, Thrombosis, and Vascular Biology (2008), 28(6), 1084-1089
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English
OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 149:416532 CA
TI KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
AU Chou, Chuan-Chu; Lunn, Charles A.; Murgolo, Nicholas J.
CS Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
SO Expert Review of Molecular Diagnostics (2008), 8(2), 179-187
CODEN: ERMDCW; ISSN: 1473-7159
PB Future Drugs Ltd.
DT Journal; General Review
LA English
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 149:393817 CA
TI Modeling of the inhibition of the intermediate-conductance Ca²⁺-activated K⁺ channel (IKCa1) by some triarylmethanes using quantum chemical

properties derived from Ab Initio calculations
AU Fernandez, Michael; Caballero, Julio
CS Molecular Modeling Group, Center for Biotechnological Studies, University
of Matanzas, Matanzas, Cuba
SO QSAR & Combinatorial Science (2008), 27(7), 866-875
CODEN: QCSSAU; ISSN: 1611-020X
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 33 CA COPYRIGHT 2010 ACS on STN
Full Text

AN 149:304249 CA
TI TRAM 34 inhibits the proliferation and differentiation of T lymphocytes in
rats of heart transplantation in abdominal cavity
AU Wang, You-Li; Pan, Cheng-En; Li, Xiao-Jun; Yu, Hai-Bo; Wu, Wu-Jun; Wu,
Chang-Xue
CS Department of Hepatobiliary Surgery, Xi'an Jiaotong University AFF First
Hospital, Xi'an, 710061, Peop. Rep. China
SO Zhonghua Shiyong Zhongxiyi Zazhi (2006), 19(18), 2199-2201
CODEN: ZSZZBQ; ISSN: 1607-2286
PB Zhonghua Shiyong Zhongxiyi Zazhishe
DT Journal
LA Chinese

L3 ANSWER 10 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text
AN 149:282757 CA
TI Openers of calcium-activated potassium channels and endothelium-dependent
hyperpolarizations in the guinea pig carotid artery
AU Leuranguer, V.; Gluais, P.; Vanhoutte, P. M.; Verbeuren, T. J.; Feletou,
M.
CS Departement Angiologie, Institut de Recherches Servier, Suresnes, 92150,
Fr.
SO Naunyn-Schmiedeberg's Archives of Pharmacology (2008), 377(2), 101-109
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer
DT Journal
LA English
OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text
AN 148:575812 CA
TI QSAR study for classes with a broad range of biological activity using
electronegativity descriptors for OMO-UMO quantum states. Clotrimazole
imidazole derivatives with antifungal activity
AU Anoica, Paul Gabriel; Lepadatu, Costinel I.
CS Fac. of Pharm., Univ. of Med. and Pharm. Craiova, Craiova, 200638, Rom.
SO Revue Roumaine de Chimie (2007), 52(3), 293-297
CODEN: RRCHAX; ISSN: 0035-3930
PB Editura Academiei Romane
DT Journal
LA English
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text
AN 147:397989 CA
TI Blockage of intermediate-conductance-Ca²⁺-activated K⁺ channels inhibits
progression of human endometrial cancer
AU Wang, Z. H.; Shen, B.; Yao, H. L.; Jia, Y. C.; Ren, J.; Feng, Y. J.; Wang,
Y. Z.
CS The Obstetrics and Gynecology Hospital of Medical Center, Fudan
University, Shanghai, Peop. Rep. China

SO Oncogene (2007), 26(35), 5107-5114
CODEN: ONCNES; ISSN: 0950-9232

PB Nature Publishing Group
DT Journal
LA English

OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 147:314575 CA

TI Regulation of endothelial-dependent relaxation in human systemic arteries by SKCa and IKCa channels

AU Gillham, J. C.; Myers, J. E.; Baker, P. N.; Taggart, M. J.

CS Maternal and Fetal Health Research Centre, Division of Human Development, St Mary's Hospital, Manchester, UK

SO Reproductive Sciences (2007), 14(1), 43-50

CODEN: RSECC3

PB Sage Publications

DT Journal

LA English

OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 147:292134 CA

TI Effects of compounds that influence IK (KCNN4) channels on afterhyperpolarizing potentials, and determination of IK channel sequence, in guinea pig enteric neurons

AU Nguyen, Trung V.; Matsuyama, Hayato; Baeli, Jonathan; Hunne, Billie; Fowler, Christopher J.; Smith, Julia E.; Nurgali, Kulmira; Furness, John B.

CS Department of Anatomy and Cell Biology and Centre for Neuroscience, University of Melbourne, Victoria, Australia

SO Journal of Neurophysiology (2007), 97(3), 2024-2031

CODEN: JONEA4; ISSN: 0022-3077

PB American Physiological Society

DT Journal

LA English

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 147:273495 CA

TI TRAM-34 inhibits nonselective cation channels

AU Schilling, Tom; Eder, Claudia

CS Medical Faculty Charite, Institute of Physiology, Berlin, 10117, Germany

SO Pfluegers Archiv (2007), 454(4), 559-563

CODEN: PFLABK; ISSN: 0031-6768

PB Springer GmbH

DT Journal

LA English

OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 147:45588 CA

TI AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers

AU Moritoki, Yuki; Lian, Zhe-Xiong; Wulff, Heike; Yang, Guo-Xiang; Chuang, Ya-Hui; Lan, Ruth Y.; Ueno, Yoshiyuki; Ansari, Aftab A.; Coppel, Ross L.; Mackay, Ian R.; Gershwin, M. Eric

CS Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis, Davis, CA, USA

SO Hepatology (Hoboken, NJ, United States) (2007), 45(2), 314-322

CODEN: HPTLD9; ISSN: 0270-9139
PB John Wiley & Sons, Inc.
DT Journal
LA English
OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 146:513548 CA
TI Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications
AU Wulff, Heike; Kolski-Andreaco, Aaron; Sankaranarayanan, Ananthakrishnan; Sabatier, Jean-Marc; Shakottai, Vikram
CS Department of Medical Pharmacology and Toxicology, University of California, Davis, CA, 95616, USA
SO Current Medicinal Chemistry (2007), 14(13), 1437-1457
CODEN: CMCHE7; ISSN: 0929-8673
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
OSC.G 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
RE.CNT 299 THERE ARE 299 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 146:394208 CA
TI Novel 384-well population patch clamp electrophysiology assays for Ca²⁺-activated K⁺ channels
AU John, Victoria H.; Dale, Tim J.; Hollands, Emma C.; Chen, Mao Xiang; Partington, Leanne; Downie, David L.; Meadows, Helen J.; Trezise, Derek J.
CS Department of Assay Development, Discovery Research Biology, GlaxoSmithKline Research & Development, Stevenage, Hertfordshire, SG7 5NJ, UK
SO Journal of Biomolecular Screening (2007), 12(1), 50-60
CODEN: JBISF3; ISSN: 1087-0571
PB Sage Publications
DT Journal
LA English
OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 146:351354 CA
TI Intermediate-conductance calcium-activated potassium channel inhibitors for the treatment and/or prevention of atherosclerosis
IN Wulff, Heike; Chandy, George K.; Miura, Hiroto
PA The University of California, USA; MCW Research Foundation Inc.
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007033307	A2	20070322	WO 2006-US35789	20060912
	WO 2007033307	A3	20070621		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MN, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 CA 2620923 A1 20070322 CA 2006-2620923 20060912
 EP 1924259 A2 20080528 EP 2006-814643 20060912
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 US 20090306159 A1 20091210 US 2008-66381 20081121
 PRAI US 2005-716859P P 20050913
 WO 2006-US35789 W 20060912

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 146:351354

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 20 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 144:343068 CA
 TI Genetic neural network modeling of the selective inhibition of the intermediate-conductance Ca^{2+} -activated K^+ channel by some triarylmethanes using topological charge indexes descriptors
 AU Caballero, Julio; Garriga, Miguel; Fernandez, Michael
 CS Molecular Modeling Group, Center for Biotechnological Studies, Faculty of Agronomy, University of Matanzas, Matanzas, 44740, Cuba
 SO Journal of Computer-Aided Molecular Design (2005), 19(11), 771-789
 CODEN: JCACDQ; ISSN: 0920-654X
 PB Springer
 DT Journal
 LA English
 OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 144:114563 CA
 TI Endovascular stent coated with potassium channel blocker
 IN Yang, Baofeng; Yue, Peng; Cui, Hao
 PA Harbin Medical University, Peop. Rep. China
 SO Faming Zhuanli Shengqing Gongkai Shuomingshu, 6 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1600384	A	20050330	CN 2004-10043944	20041019
PRAI CN 2004-10043944		20041019		

L3 ANSWER 22 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 144:34383 CA
 TI Possible role for K^+ in endothelium-derived hyperpolarizing factor-linked dilatation in rat middle cerebral artery
 AU McNeish, Alister J.; Dora, Kim A.; Garland, Christopher J.
 CS Department of Pharmacy and Pharmacology, The University of Bath, Claverton Down, UK
 SO Stroke (2005), 36(7), 1526-1532
 CODEN: SJCCA7; ISSN: 0039-2499
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 143:73542 CA
 TI The phosphatidylinositol 3-phosphate phosphatase myotubularin-related protein 6 (MTMR6) is a negative regulator of the Ca^{2+} -activated K^+ channel KCa3.1
 AU Srivastava, Shekhar; Li, Zhai; Lin, Lin; Liu, GongXin; Ko, Kyung; Coetzee, William A.; Skolnik, Edward Y.
 CS Department of Pharmacology, Skirball Institute of Biomolecular Medicine,

SO New York University School of Medicine, New York, NY, 10016, USA
Molecular and Cellular Biology (2005), 25(9), 3630-3638
CODEN: MCEBD4; ISSN: 0270-7306

PB American Society for Microbiology

DT Journal

LA English

OSC.G 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 33 CA COPYRIGHT 2010 ACS on STN
Full Text

AN 142:456581 CA

TI Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice

AU Reich, Eva-Pia; Cui, Long; Yang, Lily; Pugliese-Sivo, Catherine; Golovko, Andrei; Petro, Mary; Vassileva, Galya; Chu, Inhou; Nameir, Amin A.; Zhang, Li-Kang; Liang, Xian; Kozlowski, Joseph A.; Narula, Satwant K.; Zavodny, Paul J.; Chou, Chuan-Chu

CS Schering-Plough Research Institute, Kenilworth, NJ, USA

SO European Journal of Immunology (2005), 35(4), 1027-1036
CODEN: EJIMAF; ISSN: 0014-2980

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

OSC.G 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 33 CA COPYRIGHT 2010 ACS on STN
Full Text

AN 142:456410 CA

TI Selective Blockade of the Intermediate-Conductance Ca²⁺-Activated K+ Channel Suppresses Proliferation of Microvascular and Macrovascular Endothelial Cells and Angiogenesis In Vivo

AU Grgic, Ivica; Eichler, Ines; Heinau, Philipp; Si, Han; Brakemeier, Susanne; Hoyer, Joachim; Koehler, Ralf

CS Department of Nephrology, Charite, Campus Benjamin Franklin, Berlin, Department of Internal Medicine-Nephrology, Philipps-University, Marburg, Germany

SO Arteriosclerosis, Thrombosis, and Vascular Biology (2005), 25(4), 704-709
CODEN: ATVBFA; ISSN: 1079-5642

PB Lippincott Williams & Wilkins

DT Journal

LA English

OSC.G 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 33 CA COPYRIGHT 2010 ACS on STN
Full Text

AN 141:388164 CA

TI Pharmacology of the human red cell voltage-dependent cation channel Part I. Activation by clotrimazole and analogues

AU Barksmand, Trine L.; Kristensen, Berit I.; Christophersen, Palle; Bennekou, Poul

CS The August Krogh Institute, University of Copenhagen, Copenhagen, DK-2100, Denmark

SO Blood Cells, Molecules, & Diseases (2004), 32(3), 384-388
CODEN: BCMDFX; ISSN: 1079-9796

PB Elsevier Science

DT Journal

LA English

OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 33 CA COPYRIGHT 2010 ACS on STN
Full Text

AN 140:395571 CA

TI Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls

IN Koehler, Ralf; Wulff, Heike; Hoyer, Joachim; Chandy, K. George; Cahalan, Michael D
PA The Regents of the University of California, USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039330	A2	20040513	WO 2003-US34837	20031030
	WO 2004039330	A3	20040722		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2503962	A1	20040513	CA 2003-2503962	20031030
AU	2003287445	A1	20040525	AU 2003-287445	20031030
EP	1562590	A2	20050817	EP 2003-781681	20031030
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US	20090048270	A1	20090219	US 2007-533060	20070312
PRAI	US 2002-422712P	P	20021030		
	WO 2003-US34837	W	20031030		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:395571

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 140:297077 CA
TI Blockage of intermediate-conductance Ca²⁺-activated K⁺ channels inhibit human pancreatic cancer cell growth *in vitro*
AU Jaeger, Heike; Dreker, Tobias; Buck, Anita; Giehl, Klaudia; Gress, Thomas; Grissmer, Stephan
CS Department of Applied Physiology, University of Ulm, Ulm, Germany
SO Molecular Pharmacology (2004), 65(3), 630-638
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 139:362736 CA
TI Blockade of the Intermediate-Conductance Calcium-Activated Potassium Channel as a New Therapeutic Strategy for Restenosis
AU Koehler, Ralf; Wulff, Heike; Eichler, Ines; Kneifel, Marlene; Neumann, Daniel; Knorr, Andrea; Grgic, Ivica; Kaempfe, Doris; Si, Han; Wibawa, Judith; Real, Robert; Borner, Klaus; Brakemeier, Susanne; Orzechowski, Hans-Dieter; Reusch, Hans-Peter; Paul, Martin; Chandy, K. George; Hoyer, Joachim
CS Departments of Nephrology, Benjamin Franklin Medical Center, Berlin, Germany
SO Circulation (2003), 108(9), 1119-1125
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 136:144903 CA

TI Selective blockade of T lymphocyte K⁺ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis

AU Beeton, Christine; Wulff, Heike; Barbaria, Jocelyne; Clot-Faybesse, Olivier; Pennington, Michael; Bernard, Dominique; Cahalan, Michael D.; Chandy, K. George; Beraud, Evelyne

CS Laboratoire d'Immunologie, Faculte de Medecine, Marseille, 13385, Fr.

SO Proceedings of the National Academy of Sciences of the United States of America (2001), 98(24), 13942-13947

CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

OSC.G 114 THERE ARE 114 CAPLUS RECORDS THAT CITE THIS RECORD (114 CITINGS)

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 136:79251 CA

TI Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1

AU Wulff, Heike; Gutman, George A.; Cahalan, Michael D.; Chandy, K. George

CS Departments of Physiology and Biophysics, University of California, Irvine, CA, 92697, USA

SO Journal of Biological Chemistry (2001), 276(34), 32040-32045

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

OSC.G 41 THERE ARE 41 CAPLUS RECORDS THAT CITE THIS RECORD (41 CITINGS)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 33 CA COPYRIGHT 2010 ACS on STN

Full Text

AN 135:107324 CA

TI Synthesis of triarylmethane compounds (e.g. triarylpyrazoles) and use to selectively inhibit the calcium-activated K⁺ channel

IN Chandy, K. George; Wulff, Heike; Cahalan, Michael D.; Grismer, Stephan;

Rauer, Heiko J.; Miller, Mark J.

PA The Regents of the University of California, USA

SO PCT Int. Appl., 55 PP.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001049663	A2	20010712	WO 2001-US326	20010105
WO 2001049663	A3	20020207		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6803375	B1	20041012	US 2000-479391	20000106
CA 2396595	A1	20010712	CA 2001-2396595	20010105
EP 1248614	A2	20021016	EP 2001-901766	20010105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 7235577	B1	20070626	US 2003-402532	20030328
US 20070293554	A1	20071220	US 2007-805763	20070525
PRAI US 2000-479391	A	20000106		
WO 2001-US326	W	20010105		

US 2003-402532 A3 20030328
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 135:107324
 OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L3 ANSWER 33 OF 33 CA COPYRIGHT 2010 ACS on STN
Full Text
 AN 133:202592 CA
 TI Design of a potent and selective inhibitor of the intermediate-conductance Ca²⁺-activated K⁺ channel, IKCa1: a potential immunosuppressant
 AU Wulff, Heike; Miller, Mark J.; Hansel, Wolfram; Grissmer, Stephan;
 Cahalan, Michael D.; Chandy, K. George
 CS Department of Physiology and Biophysics, University of California, Irvine,
 CA, 92697, USA
 SO Proceedings of the National Academy of Sciences of the United States of
 America (2000), 97(14), 8151-8156
 CODEN: PNASA6; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 OSC.G 191 THERE ARE 191 CAPLUS RECORDS THAT CITE THIS RECORD (192 CITINGS)
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file uspatall
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 FULL ESTIMATED COST ENTRY SESSION
 45.82 62.22

FILE 'USPATFULL' ENTERED AT 18:51:17 ON 17 FEB 2010
 CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 18:51:17 ON 17 FEB 2010
 CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:51:17 ON 17 FEB 2010
 CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 12
 L4 6 L2

=> d 1-6

L4 ANSWER 1 OF 6 USPATFULL on STN

Full Text
 AN 2009:341984 USPATFULL
 TI Inhibition of Intermediate-Conductance Calcium Activated Potassium
 Channels in the Treatment and/or Prevention of Atherosclerosis
 IN Wulff, Heike, Davis, CA, UNITED STATES
 Chandy, George K., Laguna Beach, CA, UNITED STATES
 Miura, Hiroto, Milwaukee, WI, UNITED STATES
 PA The Regents of the University, Oakland, CA, UNITED STATES (U.S.
 corporation)
 PI US 20090306159 A1 20091210
 AI US 2006-6381 A1 20060912 (12)
 WO 2006-US35789 20060912
 PCT 20081121 date
 PRAI US 2005-716859P 20050913 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 790
 INCL INCLM: 514/381.000
 INCLS: 514/406.000
 NCL NCLM: 514/381.000
 NCLS: 514/406.000
 IC IPCI A61K0031-415 [I,A]; A61K0031-41 [I,A]; A61P0009-10 [I,A];
 A61P0009-00 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 6 USPATFULL on STN
Full Text

AN 2009:53090 USPATFULL
TI Compounds, Methods And Devices for Inhibiting Neoproliferative Changes
in Blood Vessel Walls
IN Koehler, Ralf, Berlin, GERMANY, FEDERAL REPUBLIC OF
Wulff, Heike, Davis, CA, UNITED STATES
Hoyer, Joachim, Berlin, GERMANY, FEDERAL REPUBLIC OF
Chandy, K. George, Laguna Beach, CA, UNITED STATES
PI US 20090048270 A1 20090219
AI US 2003-533060 A1 20031030 (10)
WO 2003-US34837 20031030
PRAI US 2002-422712P 20021030 (60)
DT Utility
FS APPLICATION
LN.CNT 1621
INCL INCLM: 514/256.000
INCLS: 514/648.000; 514/617.000; 514/352.000; 514/413.000; 514/370.000;
514/381.000; 514/394.000; 514/407.000
NCL NCLM: 514/256.000
NCLS: 514/352.000; 514/370.000; 514/381.000; 514/394.000; 514/407.000;
514/413.000; 514/617.000; 514/648.000
IC IPCI A61K0031-505 [I,A]; A61K0031-136 [I,A]; A61K0031-165 [I,A];
A61K0031-426 [I,A]; A61K0031-4184 [I,A]; A61K0031-4164 [I,C*];
A61P0009-00 [I,A]; A61K0031-415 [I,A]; A61K0031-41 [I,A];
A61K0031-4035 [I,A]; A61K0031-403 [I,C*]; A61K0031-44 [I,A]
IPCR A61K0031-505 [I,C]; A61K0031-505 [I,A]; A61K0031-136 [I,A]; A61K0031-165
[I,C]; A61K0031-136 [I,A]; A61K0031-165 [I,C]; A61K0031-165
[I,A]; A61K0031-403 [I,C]; A61K0031-4035 [I,A]; A61K0031-41
[I,C]; A61K0031-41 [I,A]; A61K0031-415 [I,C]; A61K0031-415 [I,A];
A61K0031-4164 [I,C]; A61K0031-4184 [I,A]; A61K0031-426 [I,C];
A61K0031-426 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A];
A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0009-10 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 6 USPATFULL on STN

Full Text

AN 2007:1335650 USPATFULL
TI Non-peptide inhibition of T-lymphocyte activation and therapies related
thereto
IN Chandy, K. George, Laguna Beach, CA, UNITED STATES
Wulff, Heike, Irvine, CA, UNITED STATES
Cahalan, Michael D., Laguna Beach, CA, UNITED STATES
Grismer, Stephan, Blaustein, GERMANY, FEDERAL REPUBLIC OF
Rauer, Heiko J., Irvine, CA, UNITED STATES
Miller, Mark J., Brea, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 20070293554 A1 20071220
AI US 2007-805763 A1 20070525 (11)
RLI Division of Ser. No. US 2003-402532, filed on 28 Mar 2003, GRANTED, Pat.
No. US 7235577 Division of Ser. No. US 2000-479391, filed on 6 Jan 2000,
GRANTED, Pat. No. US 6803375
DT Utility
FS APPLICATION
LN.CNT 1371
INCL INCLM: 514/381.000
INCLS: 514/406.000; 514/408.000; 514/730.000
NCL NCLM: 514/381.000
NCLS: 514/406.000; 514/408.000; 514/730.000
IC IPCI A61K0031-40 [I,A]; A61K0031-065 [I,A]; A61K0031-045 [I,C*];
A61K0031-41 [I,A]; A61K0031-415 [I,A]; A61P0037-02 [I,A];
A61P0037-00 [I,C*]
IPCR A61K0031-40 [I,C]; A61K0031-40 [I,A]; A61K0031-045 [I,C];
A61K0031-065 [I,A]; A61K0031-41 [I,C]; A61K0031-41 [I,A];
A61K0031-415 [I,C]; A61K0031-415 [I,A]; A61P0037-00 [I,C];
A61P0037-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 6 USPATFULL on STN

Full Text

AN 2007:164999 USPATFULL
TI Non-peptide inhibition of T-lymphocyte activation and therapies related
thereto

IN Chandy, K. George, Laguna Beach, CA, UNITED STATES
Wulff, Heike, Irvine, CA, UNITED STATES
PA The Regents of the University of California, Oakland, CA, UNITED STATES
(U.S. corporation)
PI US 7235577 B1 20070626
AI US 2003-402532 20030328 (10)
RLI Division of Ser. No. US 2000-479391, filed on 6 Jan 2000, Pat. No. US
6803375, issued on 12 Oct 2004
DT Utility
FS GRANTED
LN.CNT 1449
INCL INCLM: 514/406.000
NCL NCLM: 514/406.000
IC IPCI A61K0031-415 [I,A]
IPCR A61K0031-415 [I,C]; A61K0031-415 [I,A]; A61K0031-16 [I,C*];
A61K0031-16 [I,A]; A61K0031-275 [I,C*]; A61K0031-277 [I,A];
A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61K0031-41 [I,C*];
A61K0031-41 [I,A]; A61K0031-425 [I,C*]; A61K0031-425 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 6 USPATFULL on STN

Full Text

AN 2003:89399 USPATFULL
TI Non-peptide inhibition of T-lymphocyte activation and therapies related
thereto
IN Chandy, K. George, Laguna Beach, CA, United States
Wulff, Heike, Irvine, CA, United States
Cahalan, Michael D., Laguna Beach, CA, United States
Grismer, Stephan, Blaustein, GERMANY, FEDERAL REPUBLIC OF
Rauer, Heiko J., Irvine, CA, United States
Miller, Mark J., Brea, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6541494 B1 20030401
US 6803375 B1 20041012
AI US 2000-479391 20000106 (9)
DT Utility
FS GRANTED
LN.CNT 1387
INCL INCLM: 514/372.000
INCLS: 514/365.000; 514/609.000
NCL NCLM: 514/372.000
NCLS: 514/365.000; 514/609.000
IC [7]
ICM A61K0031-425
ICS A61K0031-16
IPCI A61K0031-425 [ICM,7]; A61K0031-16 [ICS,7]
IPCI-2 A01K0043-495 [ICM,7]
IPCR A61K0031-16 [I,C*]; A61K0031-16 [I,A]; A61K0031-275 [I,C*];
A61K0031-277 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A];
A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-415 [I,C*];
A61K0031-415 [I,A]; A61K0031-425 [I,C*]; A61K0031-425 [I,A]
EXF 514/372; 514/365; 514/609
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 6 USPAT2 on STN

Full Text

AN 2003:89399 USPAT2
TI Non-peptide inhibition of T-lymphocyte activation and therapies related
thereto
IN Chandy, K. George, Laguna Beach, CA, United States
Wulff, Heike, Irvine, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6803375 B1 20041012
AI US 2000-479391 20000106 (9)
DT Utility
FS GRANTED
LN.CNT 1389
INCL INCLM: 514/310.000
INCLS: 514/365.000; 514/609.000
NCL NCLM: 514/372.000

IC NCLS: 514/365.000; 514/609.000
[7]
ICM A01K043-495
IPCI A61K0031-425 [ICM,7]; A61K0031-16 [ICS,7]
IPCI-2 A01K0043-495 [ICM,7]
IPCR A61K0031-16 [I,C*]; A61K0031-16 [I,A]; A61K0031-275 [I,C*];
A61K0031-277 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A];
A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-415 [I,C*];
A61K0031-415 [I,A]; A61K0031-425 [I,C*]; A61K0031-425 [I,A]
EXF 514/372; 514/365; 514/609
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s (stenosis or restenosis)
L5 47024 (STENOSIS OR RESTENOSIS)

=> s (stenosis or restenosis)/clm
L6 7005 (STENOSIS OR RESTENOSIS)/CLM

=> s (implant? and stent?)
L7 27185 (IMPLANT? AND STENT?)

=> s (implant? and stent?)/clm
L8 4601 (IMPLANT? AND STENT?)/CLM

=> s 15 and 17
L9 13468 L5 AND L7

=> s 16 and 18
L10 620 L6 AND L8

=> s (coat?)
L11 1723144 (COAT?)

=> s (coat?)/clm
L12 454731 (COAT?)/CLM

=> s 19 and 111
L13 10648 L9 AND L11

=> s 110 and 112
L14 396 L10 AND L12

=> s (clotrimazole)
L15 5721 (CLOTTRIMAZOLE)

=> s (clotrimazole)/clm
L16 673 (CLOTTRIMAZOLE)/CLM

=> s 113 and 115
L17 269 L13 AND L15

=> s 114 and 116
L18 2 L14 AND L16

=> d 1-2

L18 ANSWER 1 OF 2 USPATFULL on STN

Full Text

AN 2008:227367 USPATFULL
TI Coating of the Entire Surface of Endoprostheses
IN Horres, Roland, Stolberg, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Michael, Eschweiler, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Erika, Eschweiler, GERMANY, FEDERAL REPUBLIC OF
Linssen, Marita, Aachen, GERMANY, FEDERAL REPUBLIC OF
Caspers, Roger, Inden, GERMANY, FEDERAL REPUBLIC OF
Styrenik, Michaela, Eschweiler, GERMANY, FEDERAL REPUBLIC OF
PI US 20080199506 A1 20080821
AI US 2006-913545 A1 20060503 (11)
WO 2006-DE766 20060503
PRAI DE 2005-102005021622 20050505
20071102 PCT 371 date

US 2005-687340P 20050606 (60)
DT Utility
FS APPLICATION
LN.CNT 1866
INCL INCLM: 424/423.000
INCLS: 427/022.400; 427/022.500
NCL NCLM: 424/423.000
NCLS: 427/002.240; 427/002.250
IC IPCI A61F0002-82 [I,A]; A61L0027-14 [I,A]; A61L0027-54 [I,A];
A61L0027-00 [I,C*]
IPCR A61F0002-82 [I,C]; A61F0002-82 [I,A]; A61L0027-00 [I,C];
A61L0027-14 [I,A]; A61L0027-54 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 2005:203253 USPATFULL
TI Compounds and method for coating surfaces in a haemocompatible manner
IN Horres, Roland, Stolberg, GERMANY, FEDERAL REPUBLIC OF
Linssen, Marita Katarina, Aachen, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Michael, Eschweiler, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Erika, Eschweiler, GERMANY, FEDERAL REPUBLIC OF
Di Baise, Donato, Aachen, GERMANY, FEDERAL REPUBLIC OF
Faust, Volker, Aachen, GERMANY, FEDERAL REPUBLIC OF
PI US 20050176678 A1 20050811
AI US 2003-513982 A1 20030415 (10)
WO 2003-DE1253 20030415
PRAI DE 2002-10221055 20020510
US 2003-378676P 20020509 (60)
DT Utility
FS APPLICATION
LN.CNT 2492
INCL INCLM: 514/054.000
INCLS: 536/053.000
NCL NCLM: 514/054.000
NCLS: 536/053.000
IC [7]
ICM A61K031-728
IPCI A61K031-728 [ICM,7]; A61K031-726 [ICM,7,C*]
IPCR A61K031-726 [I,C*]; A61K031-728 [I,A]; A61L0031-08 [I,C*];
A61L0031-10 [I,A]; A61L0033-00 [I,C*]; A61L0033-08 [I,A];
C09D0105-00 [I,C*]; C09D0105-08 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:43:35 ON 17 FEB 2010)

FILE 'REGISTRY' ENTERED AT 18:43:42 ON 17 FEB 2010
E CLOTRIMAZOLE/CN

L1 1 S E3
E TRAM 34/CN
L2 1 S E3

FILE 'CA' ENTERED AT 18:45:01 ON 17 FEB 2010
L3 33 S L2

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 18:51:17 ON 17 FEB 2010
L4 6 S L2
L5 47024 S (STENOSIS OR RESTENOSIS)
L6 7005 S (STENOSIS OR RESTENOSIS)/CLM
L7 27185 S (IMPLANT? AND STENT?)
L8 4601 S (IMPLANT? AND STENT?)/CLM
L9 13468 S L5 AND L7
L10 620 S L6 AND L8
L11 1723144 S (COAT?)
L12 454731 S (COAT?)/CLM
L13 10648 S L9 AND L11
L14 396 S L10 AND L12
L15 5721 S (CLOTRIMAZOLE)
L16 673 S (CLOTRIMAZOLE)/CLM

L17 269 S L13 AND L15
L18 2 S L14 AND L16

-> d l14 356-396

L14 ANSWER 356 OF 396 USPATFULL on STN

Full Text

AN 89:938 USPATFULL
TI Stent for use following balloon angioplasty
IN Regan, Barrie F., 2260 Redington Rd., Hillsborough, CA, United States 94010
PI US 4795458 19890103
AI US 1987-69364 19870702 (7)
DT Utility
FS Granted
LN.CNT 256
INCL INCLM: 623/001.000
INCLS: 623/012.000; 128/343.000; 427/002.000
NCL NCLM: 623/001.190
NCLS: 606/191.000; 606/194.000
IC [4]
ICM A61F002-06
ICS A61F002-04
IPCI A61F0002-06 [ICM,4]; A61F0002-04 [ICS,4]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-06 [I,C*];
A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-84 [I,A];
A61F0002-88 [I,A]; A61L0031-08 [I,C*]; A61L0031-08 [I,A]
EXF 623/1; 623/12; 623/66; 128/341; 128/343; 128/745; 128/324R; 128/DIG.22;
128/303R; 604/272; 604/273; 604/274; 427/2

L14 ANSWER 357 OF 396 USPAT2 on STN

Full Text

AN 2008:361544 USPAT2
TI Use of K-252a and Kinase Inhibitors for the Prevention or Treatment of HMGB1-Associated Pathologies
IN FUMERO, Silvano, Via delle Germane 11, Ivrea (TO), ITALY 10015
PILATO, Francesco, Via G. Parini, 9, Milano, ITALY 20121
BARONE, Domenico, Corso Rosselli, 66, Torino, ITALY 10129
BERTARIONE RAVA ROSSA, Luisa, Via Circonvallazione, 17/2, Pavone Canavese (TO), ITALY 10018
MAINERO, Valentina, Via San Gaudenzio, 5, Ivrea (TO), ITALY 10015
TRAVERSA, Silvio, Regione Mulini, 74, Palazzo Canavese, ITALY 10010
PA Creabilis Therapeutics S.P.A., Colleferro Giacoso, ITALY, 10010
(non-U.S. corporation)
Bio3Research srl, Milano, ITALY, 20121 (non-U.S. corporation)
PI US 20090191253 A2 20090730
AI US 2007-658701 A1 20070129 (11)
PRAI US 2005-647007P 20050127 (60)
DT Utility
FS APPLICATION
LN.CNT 1528
INCL INCLM: 424/423.000
INCLS: 514/410.000; 424/173.100; 424/153.100; 514/002.000
NCL NCLM: 424/423.000
NCLS: 424/153.100; 424/173.100; 514/002.000; 514/410.000
IC IPCI A61F0002-04 [I,A]; A61K0031-407 [I,A]; A61P0037-02 [I,A];
A61P0037-00 [I,C*]; A61P0009-00 [I,A]; A61K0039-395 [I,A];
A61K0031-7105 [I,A]; A61K0038-02 [I,A]; A61K0031-713 [I,A];
IPC1-2 A61F0002-04 [I,A]; A61K0031-407 [I,A]; A61P0037-02 [I,A];
A61P0037-00 [I,C*]; A61P0009-00 [I,A]; A61K0039-395 [I,A];
A61K0031-7105 [I,A]; A61K0038-02 [I,A]; A61K0031-713 [I,A];
IPCR A61F0002-04 [I,C]; A61F0002-04 [I,A]; A61K0031-407 [I,C];
A61K0031-407 [I,A]; A61K0031-7105 [I,C]; A61K0031-7105 [I,A];
A61K0031-713 [I,C]; A61K0031-713 [I,A]; A61K0038-02 [I,C];
A61K0038-02 [I,A]; A61K0039-395 [I,C]; A61K0039-395 [I,A];
A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0037-00 [I,C];
A61P0037-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 358 OF 396 USPAT2 on STN

Full Text

AN 2008:239635 USPAT2

TI C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
IN Marx, Steven O., New York, NY, UNITED STATES
Marks, Andrew R., Larchmont, NY, UNITED STATES
PA The Trustees of Columbia University in the City of New York, New York, NY, UNITED STATES (U.S. corporation)
US 7662178 B2 20100216
AI US 2008-150695 20080429 (12)
RLI Continuation of Ser. No. US 2002-326936, filed on 20 Dec 2002, Pat. No. US 7364586
PRAI US 2001-343030P 20011221 (60)
DT Utility
FS GRANTED
LN.CNT 917
INCL INCLM: 623/001.420
INCLS: 623/001.430
NCL NCLM: 623/001.420
NCLS: 623/001.430
IC IPCI A61F0002-06 [I,A]
IPCI-2 A61F0002-82 [I,A]; A61F0002-00 [I,A]
IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61L0031-08 [I,C*];
A61L0031-10 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
EXF 623/1.15; 623/1.16; 623/1.17; 623/1.19; 623/1.2; 623/1.21; 623/1.22;
623/1.42; 623/1.43; 623/1.44; 623/1.45; 623/1.46; 623/1.47; 623/1.48;
623/1.49; 427/2.24; 427/2.25; 427/456

L14 ANSWER 359 OF 396 USPAT2 on STN

Full Text

AN 2008:59020 USPAT2
TI Medical devices, drug coatings and methods for maintaining the drug coatings thereon
IN Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopelianos, Angelo George, White House Station, NJ, UNITED STATES
Falotico, Robert, Belle Mead, NJ, UNITED STATES
PA Cordis Corporation, Miami Lakes, FL, UNITED STATES (U.S. corporation)
Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)
PI US 7591844 B2 20090922
AI US 2007-941351 20071116 (11)
RLI Continuation of Ser. No. US 2007-782770, filed on 25 Jul 2007, ABANDONED
Continuation of Ser. No. US 2006-437572, filed on 19 May 2006, PENDING
Continuation of Ser. No. US 2003-636435, filed on 7 Aug 2003, Pat. No. US 7056550 Continuation of Ser. No. US 2001-962496, filed on 25 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, ABANDONED
DT Utility
FS GRANTED
LN.CNT 2370
INCL INCLM: 623/001.120
INCLS: 623/001.430; 623/001.460; 623/001.490; 428/421.000; 427/002.250
NCL NCLM: 623/001.120; 623/001.200
NCLS: 427/002.250; 428/421.000; 623/001.430; 623/001.460; 623/001.490;
623/001.420
IC IPCI A61F0002-06 [I,A]; B0500003-02 [I,A]
IPCI-2 A61F0002-06 [I,A]; B32B0027-00 [I,A]; A61L0033-00 [I,A]
IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61L0033-00 [I,C];
A61L0033-00 [I,A]; B32B0027-00 [I,C]; B32B0027-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 360 OF 396 USPAT2 on STN

Full Text

AN 2007:148297 USPAT2
TI Rapamycin peptides conjugates: synthesis and uses thereof
IN Sharma, Sanjay K., Edmonton, CANADA
Woo, Thomas, Edmonton, CANADA
Naicker, Selvaraj, Edmonton, CANADA
PA Quest Pharmatech, Inc., Edmonton, Alberta, CANADA (non-U.S. corporation)
PI US 7659244 B2 20100209
WO 2005042567 20050512
AI US 2004-578105 20041103 (10)
WO 2004-CA1918 20041103

DT Utility
 FS GRANTED
 LN.CNT 1154
 INCL INCLM: 514/009.000
 INCLS: 530/317.000
 NCL NCLM: 514/009.000
 NCLS: 530/317.000
 IC IPCI A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]; C07D0491-14 [I,A];
 C07D0491-00 [I,C*]
 IPCI-2 A61K0038-12 [I,A]; C07K0007-50 [I,A]; C07K0007-00 [I,C*]
 IPCR A61K0031-4738 [I,C]; A61K0031-4745 [I,A]; A61K0038-00 [N,C*];
 A61K0038-00 [N,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A];
 C07D0491-00 [I,C]; C07D0491-14 [I,A]; C07D0498-00 [I,C*];
 C07D0498-18 [I,A]; C07K0005-00 [I,C*]; C07K0005-087 [I,A];
 C07K0005-107 [I,A]; C07K0007-00 [I,C*]; C07K0007-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 361 OF 396 USPAT2 on STN

Full Text

AN 2007:68190 USPAT2
 TI Rate limiting barriers for implantable devices and methods for
 fabrication thereof
 IN Roorda, Wouter E., Palo Alto, CA, UNITED STATES
 Hossainy, Syed F. A., Fremont, CA, UNITED STATES
 Ding, NL, San Jose, CA, UNITED STATES
 Tang, Fuh-Wei, Temecula, CA, UNITED STATES
 PA Pacetti, Stephen D., San Jose, CA, UNITED STATES
 Advanced Cardiovascular Systems, Inc., Santa Clara, CA, UNITED STATES
 (U.S. corporation)
 PI US 7622146 B2 20091124
 AI US 2006-592632 20061102 (11)
 RLI Continuation of Ser. No. US 2002-198898, filed on 18 Jul 2002, Pat. No.
 US 7175873, issued on 13 Feb 2007

DT Utility
 FS GRANTED

LN.CNT 857

INCL INCLM: 427/002.100
 INCLS: 427/002.240; 427/002.250; 427/002.280; 623/001.420; 623/001.430;
 623/001.440; 623/001.460
 NCL NCLM: 427/002.100
 NCLS: 427/002.240; 427/002.250; 427/002.280; 623/001.420; 623/001.430;
 623/001.440; 623/001.460
 IC IPCI A61L0033-00 [I,A]; B05D0003-00 [I,A]
 IPCI-2 A61L0033-00 [I,A]; A61M0025-00 [I,A]; A61F0002-06 [I,A]
 IPCR A61L0033-00 [I,C]; A61L0033-00 [I,A]; B05D0003-00 [I,C];
 B05D0003-00 [I,A]

EXF 427/2.1-2.31; 623/1.42-1.44; 623/1.46
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 362 OF 396 USPAT2 on STN

Full Text

AN 2006:321301 USPAT2
 TI Drug-eluting intravascular prostheses and methods of use
 IN Flugelman, Moshe, Haifa, ISRAEL
 PA Multi-Gene Vascular Systems Ltd., ISRAEL (non-U.S. corporation)
 PI US 7563278 B2 20090721
 AI US 2006-344870 20060131 (11)
 RLI Continuation-in-part of Ser. No. US 2002-163387, filed on 4 Jun 2002,
 Pat. No. US 7364725 Continuation-in-part of Ser. No. US 2002-164219,
 filed on 4 Jun 2002, Pat. No. US 7175658 Continuation-in-part of Ser.
 No. US 2000-620277, filed on 20 Jul 2000, ABANDONED

DT Utility
 FS GRANTED

LN.CNT 3151

INCL INCLM: 623/001.410
 INCLS: 623/001.430; 623/001.460; 623/001.480; 623/001.490; 514/044.000;
 424/093.100; 424/093.210; 536/023.100
 NCL NCLM: 623/001.410; 424/423.000
 NCLS: 424/093.100; 424/093.210; 514/044.000R; 536/023.100; 623/001.430;
 623/001.460; 623/001.480; 623/001.490; 514/012.000
 IC IPCI A61K0038-18 [I,A]; A61F0002-02 [I,A]

IPCI-2 A61F0002-06 [I,A]; A61K0031-70 [I,A]; A61K0038-21 [I,A];
 A01N0063-00 [I,A]; A01N0043-04 [I,A]; A01N0043-02 [I,C*];
 C07H0021-02 [I,A]; C07H0021-00 [I,C*]
 IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; C12N0015-09 [I,C*];
 C12N0015-09 [I,A]; A01N0043-02 [I,C]; A01N0043-04 [I,A];
 A01N0063-00 [I,C]; A01N0063-00 [I,A]; A61K0031-70 [I,C];
 A61K0031-70 [I,A]; A61K0038-18 [I,C*]; A61K0038-21 [I,C];
 A61K0038-21 [I,A]; A61L0027-00 [I,C*]; A61L0027-00 [I,A];
 A61L0027-38 [I,A]; A61L0027-50 [I,A]; C07H0021-00 [I,C];
 C07H0021-02 [I,A]; C07K0014-435 [I,C*]; C07K0014-52 [I,A];
 C12N0005-10 [I,C*]; C12N0005-10 [I,A]

L14 ANSWER 363 OF 396 USPAT2 on STN

Full Text

AN 2006:189544 USPAT2
 TI Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
 IN Pacetti, Stephen D., San Jose, CA, UNITED STATES
 Hossainy, Syed F. A., Fremont, CA, UNITED STATES
 PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, UNITED STATES (U.S. corporation)
 PI US 7202325 B2 20070410
 AI US 2005-35816 20050114 (11)
 DT Utility
 FS GRANTED
 LN.CNT 3191
 INCL INCLM: 528/272.000
 INCLS: 424/423.000; 424/078.300; 525/054.100; 525/054.200
 NCL NCLM: 528/272.000
 NCLS: 424/078.300; 424/423.000; 525/054.100; 525/054.200
 IC IPCI C08G0063-02 [I,A]; C08G0063-00 [I,C*]
 IPCI-2 C08G0063-00 [I,A]
 IPCR C08G0063-00 [I,C]; C08G0063-00 [I,A]
 EXF 424/423; 424/78.3; 525/54.1; 525/54.2; 528/272
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 364 OF 396 USPAT2 on STN

Full Text

AN 2006:181400 USPAT2
 TI Nitric oxide-producing hydrogel materials
 IN West, Jennifer L., Pearland, TX, UNITED STATES
 Masters, Kristyn Simcha, Northglenn, CO, UNITED STATES
 PA Rice University, Houston, TX, UNITED STATES (U.S. corporation)
 PI US 7651697 B2 20100126
 AI US 2005-281242 20051117 (11)
 RLI Division of Ser. No. US 1900-129418, Pat. No. US 7052711 A 371 of International Ser. No. WO 2001-US27414, filed on 4 Sep 2001 Continuation-in-part of Ser. No. US 2000-653406, filed on 1 Sep 2000, Pat. No. US 7279176
 PRAI US 1999-152054P 19990902 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1548
 INCL INCLM: 424/426.000
 NCL NCLM: 424/078.300
 NCLS: 525/054.100
 IC IPCI A61K0031-765 [I,A]; A61K0031-74 [I,C*]; C08G0063-91 [I,A]; C08G0063-00 [I,C*]
 IPCI-2 A61F0002-02 [I,A]
 IPCR A61K0031-74 [I,C]; A61K0031-765 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A]; C08G0063-00 [I,C]; C08G0063-91 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 365 OF 396 USPAT2 on STN

Full Text

AN 2006:145168 USPAT2
 TI Stent device and method
 IN Alt, Eckhard, Ottobrunn, GERMANY, FEDERAL REPUBLIC OF
 PA Boston Scientific Scimed, Inc., Maple Grove, MN, UNITED STATES (U.S. corporation)
 PI US 7625410 B2 20091201
 AI US 2006-338452 20060123 (11)

RLI Continuation of Ser. No. US 2003-443266, filed on 22 May 2003, Pat. No. US 7011680, issued on 14 Mar 2006 Continuation of Ser. No. US 2001-847626, filed on 2 May 2001, Pat. No. US 6613083, issued on 2 Sep 2003
DT Utility
FS GRANTED
LN.CNT 2719
INCL INCLM: 623/042.000
NCL NCLM: 623/042.000; 623/001.150
NCLS: 623/001.420
IC IPCI A61F0002-82 [I,A]; A61F0002-90 [I,A]
IPCI-2 A61F0002-06 [I,A]
IPCR A61F0002-82 [I,A]; A61F0002-82 [I,C]; A61F0002-90 [I,A]
EXF 623/1.42-1.54; 623/1.13; 623/1.15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 366 OF 396 USPAT2 on STN

Full Text

AN 2006:104470 USPAT2
TI Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function
IN Tijssma, Edze Jan, Maastricht, NETHERLANDS
Driessens-Levles, Anita, Reuver, NETHERLANDS
Hendriks, Marc, Brunssum, NETHERLANDS
PA Medtronic, Inc., Minneapolis, MN, UNITED STATES (U.S. corporation)
PI US 7176261 B2 20070213
AI US 2005-256582 20051021 (11)
PRAI US 2004-621462P 20041021 (60)
DT Utility
FS GRANTED
LN.CNT 1082
INCL INCLM: 525/330.300
INCLS: 514/002.000; 623/001.150; 424/426.000; 604/500.000
NCL NCLM: 525/330.300; 424/426.000
NCLS: 424/426.000; 514/002.000; 604/500.000; 623/001.150
IC IPCI A61F0002-00 [I,A]
IPCI-2 C08F0020-10 [I,A]; C08F0020-00 [I,C*]; A61K0038-08 [I,A];
A61F0002-04 [I,A]
IPCR C08F0020-00 [I,C]; C08F0020-10 [I,A]; A61F0002-04 [I,C];
A61F0002-04 [I,A]; A61K0038-08 [I,C]; A61K0038-08 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 367 OF 396 USPAT2 on STN

Full Text

AN 2005:150818 USPAT2
TI Stents and intra-luminal prostheses containing map kinase inhibitors
IN Schreiner, George F., Los Altos, CA, UNITED STATES
PA Scios, Inc., Fremont, CA, UNITED STATES (U.S. corporation)
PI US 7244441 B2 20070717
AI US 2004-951754 20040927 (10)
PRAI US 2003-506216P 20030925 (60)
DT Utility
FS GRANTED
LN.CNT 2484
INCL INCLM: 424/422.000
INCLS: 623/001.420
NCL NCLM: 424/422.000; 424/423.000
NCLS: 623/001.420
IC IPCI A61F0002-06 [ICM,7]; A61F0002-00 [ICS,7]
IPCI-2 A61F0013-00 [I,A]; A61F0002-06 [I,A]
IPCR A61F0013-00 [I,C]; A61F0013-00 [I,A]; A61F0002-00 [I,C*];
A61F0002-00 [I,A]; A61F0002-06 [I,C]; A61F0002-06 [I,A]
EXF 424/443; 424/422; 623/1.42

L14 ANSWER 368 OF 396 USPAT2 on STN

Full Text

AN 2005:145305 USPAT2
TI System method and apparatus for localized heating of tissue
IN Eggers, Philip E., Dublin, OH, UNITED STATES
Ridihalgh, John L., Columbus, OH, UNITED STATES
PA Apsara Medical Corporation, San Mateo, CA, UNITED STATES (U.S. corporation)

PI US 7567843 B2 20090728
AI US 2005-36276 20050114 (11)
RLI Division of Ser. No. US 2002-310475, filed on 5 Dec 2002, Pat. No. US 6850804 Continuation-in-part of Ser. No. US 2002-246347, filed on 18 Sep 2002, Pat. No. US 6993394 Continuation-in-part of Ser. No. US 2002-201363, filed on 23 Jul 2002, ABANDONED
PRAI US 2002-349593P 20020118 (60)
DT Utility
FS GRANTED
LN.CNT 4551
INCL INCLM: 607/103.000
INCLS: 607/096.000; 607/113.000; 600/012.000
NCL NCLM: 607/103.000
NCLS: 600/012.000; 607/096.000; 607/113.000
IC IPCI A61F0002-00 [ICM,7]
IPCI-2 A61F0007-00 [I,A]; A61F0002-00 [I,A]
IPCR A61F0007-00 [I,C]; A61F0007-00 [I,A]; A61B0017-00 [N,C*];
A61B0017-00 [N,A]; A61B0017-22 [N,C*]; A61B0017-22 [N,A];
A61B0018-04 [I,C*]; A61B0018-04 [I,A]; A61B0018-18 [N,C*];
A61B0018-18 [N,A]; A61F0002-00 [I,C]; A61F0002-00 [I,A];
A61F0007-12 [I,C*]; A61F0007-12 [I,A]; A61N0007-00 [N,C*];
A61N0007-02 [N,A]
EXF 623/1.15; 623/1.18; 607/96; 607/103; 607/116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 369 OF 396 USPAT2 on STN

Full Text

AN 2005:125141 USPAT2
TI Block copolymers of acrylates and methacrylates with fluoroalkenes
IN Claude, Charles D., Sunnyvale, CA, UNITED STATES
PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, UNITED STATES
(U.S. corporation)
PI US 7261946 B2 20070828
AI US 2003-714111 20031114 (10)
DT Utility
FS GRANTED
LN.CNT 506
INCL INCLM: 428/500.000
INCLS: 428/523.000; 623/001.100; 623/001.420
NCL NCLM: 428/500.000; 525/088.000
NCLS: 428/523.000; 623/001.100; 623/001.420
IC IPCI C08L0053-00 [ICM,7]
IPCI-2 A61L0031-10 [I,A]; A61L0031-08 [I,C*]
IPCR A61L0031-08 [I,C]; A61L0031-10 [I,A]; C08F0293-00 [I,C*];
C08F0293-00 [I,A]; C08L0053-00 [I,C*]; C08L0053-00 [I,A];
C09D0153-00 [I,C*]; C09D0153-00 [I,A]
EXF 623/1.1; 623/1.42; 623/1.15; 424/423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 370 OF 396 USPAT2 on STN

Full Text

AN 2005:123814 USPAT2
TI Polycrylates coatings for implantable medical devices
IN Roorda, Wouter E., Palo Alto, CA, UNITED STATES
Ding, Ni, San Jose, CA, UNITED STATES
Pacetti, Stephen D., San Jose, CA, UNITED STATES
Michal, Eugene T., San Francisco, CA, UNITED STATES
Shah, Ashok A., San Jose, CA, UNITED STATES
Hossainy, Syed F. A., Fremont, CA, UNITED STATES
PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, UNITED STATES
(U.S. corporation)
PI US 7247313 B2 20070724
AI US 2002-176504 20020621 (10)
RLI Continuation-in-part of Ser. No. US 2001-894293, filed on 27 Jun 2001,
ABANDONED
DT Utility
FS GRANTED
LN.CNT 951
INCL INCLM: 424/423.000
INCLS: 424/426.000; 424/400.000
NCL NCLM: 424/423.000
NCLS: 424/400.000; 424/426.000

IC IPCI A61K0047-32 [ICM,7]
IPCI-2 A61F0002-02 [I,A]; A61K0009-00 [I,A]
IPCR A61L0031-00 [I,C*]; A61L0031-00 [I,A]; A61F0002-82 [I,C*];
A61F0002-84 [I,A]; A61K0031-4353 [I,C*]; A61K0031-436 [I,A];
A61L0031-08 [I,C*]; A61L0031-10 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61F0002-02 [I,C]; A61F0002-02 [I,A];
A61K0009-00 [I,C]; A61K0009-00 [I,A]

EXF 424/423; 424/422; 424/400; 424/426; 623/1.16; 623/1.42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 371 OF 396 USPAT2 on STN

Full Text

AN 2004:328442 USPAT2
TI Drug/drug delivery systems for the prevention and treatment of vascular disease
IN Falotico, Robert, Belle Mead, NJ, UNITED STATES
Kopia, Gregory A., Hillsborough, NJ, UNITED STATES
Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
PA Cordis Corporation, Miami Lakes, FL, UNITED STATES (U.S. corporation)
PI US 7300662 B2 20071127
AI US 2004-829074 20040421 (10)
RLI Continuation-in-part of Ser. No. US 2001-850293, filed on 7 May 2001,
ABANDONED Continuation-in-part of Ser. No. US 2000-575480, filed on 19
May 2000, PENDING
PRAI US 2001-263979P 20010125 (60)
US 2001-263806P 20010124 (60)
US 2001-262614P 20010118 (60)
US 2001-262461P 20010118 (60)
US 2000-204417P 20000512 (60)
DT Utility
FS GRANTED
LN.CNT 1993
INCL INCLM: 424/424.000
INCLS: 623/001.420; 623/001.450
NCL NCLM: 424/424.000; 604/500.000
NCLS: 623/001.420; 623/001.450
IC IPCI A61N0001-30 [ICM,7]
IPCI-2 A61F0002-00 [I,A]; A61F0002-06 [I,A]
IPCR A61F0002-00 [I,C]; A61F0002-00 [I,A]; C07D0498-00 [I,C*];
C07D0498-18 [I,A]; A61B0017-00 [I,C*]; A61B0017-00 [I,A];
A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61F0002-82 [I,C*];
A61F0002-82 [I,A]; A61F0002-84 [I,A]; A61F0002-90 [I,A];
A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-4353 [I,C*];
A61K0031-436 [I,A]; A61K0031-726 [I,C*]; A61K0031-727 [I,A];
A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0045-06 [I,A];
A61K0047-30 [I,C*]; A61K0047-30 [I,A]; A61K0047-48 [I,C*];
A61K0047-48 [I,A]; A61L0031-00 [I,C*]; A61L0031-00 [I,A];
A61L0031-14 [I,C*]; A61L0031-16 [I,A]; A61M0031-00 [I,C*];
A61M0031-00 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A];
A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0009-10 [I,A];
A61P0021-00 [I,C*]; A61P0021-00 [I,A]; A61P0029-00 [I,C*];
A61P0029-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]

EXF 424/422-426; 623/1.42-1.48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 372 OF 396 USPAT2 on STN

Full Text

AN 2004:260196 USPAT2
TI Implantable or insertable medical devices containing
radiation-crosslinked polymer for controlled delivery of a therapeutic
agent
IN Richard, Robert E., Wrentham, MA, UNITED STATES
PA Boston Scientific Scimed, Inc., Maple Grove, MN, UNITED STATES (U.S.
corporation)
PI US 7241455 B2 20070710
AI US 2003-409358 20030408 (10)
DT Utility
FS GRANTED
LN.CNT 948
INCL INCLM: 424/423.000
INCLS: 514/772.300
NCL NCLM: 424/423.000

NCLS: 514/772.300; 604/890.100
IC IPCI A61F0013-00 [ICM,7]; A61K0009-22 [ICS,7]
IPCI-2 A61F0002-00 [I,A]; A61K0047-30 [I,A]
IPCR A61F0002-00 [I,C]; A61F0002-00 [I,A]; A61F0002-06 [I,C*];
A61F0002-06 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0047-30 [I,C];
A61K0047-30 [I,A]; A61M0025-00 [I,C*]; A61M0025-00 [I,A];
A61M0036-00 [I,C*]; A61M0036-00 [I,A]

EXF 424/423; 424/426; 514/772.3; 514/772.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 373 OF 396 USPAT2 on STN

Full Text

AN 2004:255297 USPAT2
TI Use of rhein or diacerhein compounds for the treatment or prevention of
vascular diseases
IN Cruz, Tony, Toronto, CANADA
PA Pastrak, Aleksandra, Toronto, CANADA
PA Transition Therapeutics Inc., Toronto, CANADA (non-U.S. corporation)
PI US 7026355 B2 20060411
AI US 2004-833593 20040427 (10)
RLI Continuation of Ser. No. US 2002-196742, filed on 15 Jul 2002, Pat. No.
US 6797727
PRAI US 2001-306111P 20010716 (60)
DT Utility
FS GRANTED
LN.CNT 657
INCL INCLM: 514/510.000
INCLS: 514/548.000; 514/569.000
NCL NCLM: 514/510.000; 514/569.000
NCLS: 514/548.000; 514/569.000; 514/621.000; 514/680.000
IC IPCI A61K0031-12 [ICM,7]; A61K0031-165 [ICS,7]; A61K0031-192 [ICS,7];
A61K0031-185 [ICS,7,C*]
IPCI-2 A61K0031-21 [I,A]; A61K0031-225 [I,A]; A61K0031-21 [I,C*];
A61K0031-19 [I,A]; A61K0031-185 [I,C*]
IPCR A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-21 [I,C*];
A61K0031-222 [I,A]; A61K0031-21 [I,A]; A61K0031-185 [I,C];
A61K0031-19 [I,A]; A61K0031-21 [I,C]; A61K0031-225 [I,A]
EXF 514/510; 514/548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 374 OF 396 USPAT2 on STN

Full Text

AN 2004:196448 USPAT2
TI Hydrogel entrapping therapeutic agent and stent with coating comprising
this
IN Won, Chee-Youb, Livingston, NJ, UNITED STATES
Zhang, Yeli, Somerville, NJ, UNITED STATES
Chu, Chih-Chang, Ithaca, NY, UNITED STATES
PA Cornell Research Foundation, Inc., Ithaca, NY, UNITED STATES (U.S.
corporation)
PI US 6905700 B2 20050614
AI US 2004-762256 20040123 (10)
RLI Continuation of Ser. No. US 143572, PENDING Division of Ser. No. US
2002-143572, filed on 13 May 2002, Pat. No. US 6716445
Continuation-in-part of Ser. No. US 2000-531451, filed on 20 Mar 2000,
Pat. No. US 6388047
PRAI US 1999-128803P 19990412 (60)
DT Utility
FS GRANTED
LN.CNT 1106
INCL INCLM: 424/426.000
INCLS: 424/484.000; 424/486.000; 424/487.000; 424/488.000; 523/105.000;
525/937.000; 602/048.000; 604/048.000
NCL NCLM: 424/426.000; 424/423.000
NCLS: 424/484.000; 424/486.000; 424/487.000; 424/488.000; 523/105.000;
525/937.000; 602/048.000; 604/048.000
IC [7]
ICM A61K009-58
ICS C08G063-08
IPCI A61K0009-14 [ICM,7]; A61F0002-00 [ICS,7]
IPCI-2 A61K0009-58 [ICM,7]; A61K0009-52 [ICM,7,C*]; C08G0063-08 [ICS,7];

IPC R C08G0063-00 [ICS,7,C*]
A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0047-36 [I,C*];
A61K0047-36 [I,A]; C08B0037-00 [I,C*]; C08B0037-02 [I,A];
C08G0018-00 [I,C*]; C08G0018-64 [I,A]; C08G0018-81 [I,A];
C08L0005-00 [I,C*]; C08L0005-02 [I,A]; C08L0067-00 [I,C*];
C08L0067-07 [I,A]
EX F 424/426; 424/484; 424/486; 424/487; 424/488; 523/105; 525/937; 602/48;
604/48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 375 OF 396 USPAT2 on STN

Full Text

AN 2004121656 USPAT2
TI Tubular vascular implants (stents) and methods for producing the same
IN Hildebrand, Gesine, Berlin, GERMANY, FEDERAL REPUBLIC OF
Tack, Johannes, Berlin, GERMANY, FEDERAL REPUBLIC OF
Kaeufer, Helmut, Mettmann, GERMANY, FEDERAL REPUBLIC OF
Wache, Hans-Martin, Berlin, GERMANY, FEDERAL REPUBLIC OF
Mueller, Thomas, Berlin, GERMANY, FEDERAL REPUBLIC OF
Ewert, Peter, Berlin, GERMANY, FEDERAL REPUBLIC OF
PA Schering AG, Berlin, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 7087078 B2 20060808
WO 2002041929 20020530
AI US 2001-432156 20011121 (10)
WO 2001-DE4424 20011121
20031124 PCT 371 date
PRAI DE 2000-10057817 20001121
US 2000-252891P 20001127 (60)
DT Utility
FS GRANTED
LN.CNT 610
INCL INCLM: 623/001.180
INCLS: 623/001.200
NCL NCLM: 623/001.180; 623/001.150
NCLS: 623/001.200
IC IPCI A61F0002-06 [ICM,7]
IPCI-2 A61F0002-06 [I,A]
IPC R A61L0031-04 [I,C*]; A61L0031-06 [I,A]; A61L0031-14 [I,C*];
A61L0031-14 [I,A]; A61L0031-16 [I,A]
EX F 623/1.15; 623/1.22; 427/2.24; 427/456

L14 ANSWER 376 OF 396 USPAT2 on STN

Full Text

AN 2004114664 USPAT2
TI Nitrosated and nitrosylated taxanes, compositions and methods of use
IN Garvey, David S., Dover, MA, United States
Letts, L. Gordon, Dover, MA, United States
Lin, Chia-En, Burlington, MA, United States
Richardson, Stewart K., Tolland, CT, United States
Wang, Tiansheng, Concord, MA, United States
PA NitroMed, Inc., Lexington, MA, United States (U.S. corporation)
PI US 6869973 B2 20050322
AI US 2003-682923 20031014 (10)
RLI Continuation of Ser. No. US 2001-886494, filed on 22 Jun 2001, now
patented, Pat. No. US 665966
PRAI US 2000-213294P 20000622 (60)
US 2000-226090P 20000818 (60)
DT Utility
FS GRANTED
LN.CNT 2962
INCL INCLM: 514/449.000
INCLS: 549/510.000; 549/511.000
NCL NCLM: 514/449.000; 514/018.000
NCLS: 549/510.000; 549/511.000; 514/509.000
IC [7]
ICM A61K031-337
ICS C07D305-14
IPCI A61K0038-06 [ICM,7]; A61K0031-21 [ICS,7]
IPCI-2 A61K0031-337 [ICM,7]; C07D0305-14 [ICS,7]; C07D0305-00 [ICS,7,C*]
IPCR A61K0031-335 [I,C*]; A61K0031-335 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A];
C07D0305-00 [I,C*]; C07D0305-14 [I,A]; C07D0409-00 [I,C*];

C07D0409-12 [I,A]
EXF 514/449; 549/510; 549/511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 377 OF 396 USPAT2 on STN

Full Text

AN 2004:63391 USPAT2
TI Method of treating a patient with a coated implantable medical device
IN Ragheb, Anthony O., West Lafayette, IN, UNITED STATES
Fearnott, Neal E., West Lafayette, IN, UNITED STATES
Voorhees, III, William D., West Lafayette, IN, UNITED STATES
Kozma, Thomas G., McHenry, IL, UNITED STATES
Bates, Brian L., Bloomington, IN, UNITED STATES
Osborne, Thomas A., Bloomington, IN, UNITED STATES
PA Cook Incorporated, Bloomington, IN, UNITED STATES (U.S. corporation)
MED Institute, Inc., West Lafayette, IN, UNITED STATES (U.S. corporation)
PI US 7445628 B2 20081104
AI US 2003-414444 20030414 (10)
RLI Continuation of Ser. No. US 2002-223415, filed on 19 Aug 2002, PENDING
Continuation-in-part of Ser. No. US 1998-27054, filed on 20 Feb 1998,
Pat. No. US 6774278 Continuation-in-part of Ser. No. US 1996-645646,
filed on 16 May 1996, Pat. No. US 6096070, issued on 1 Aug 2000
Continuation-in-part of Ser. No. US 1995-484532, filed on 7 Jun 1995,
Pat. No. US 5609629, issued on 11 Mar 1997
PRAI US 1997-38459P 19970220 (60)
DT Utility
FS GRANTED
LN.CNT 1854
INCL INCLM: 623/001.420
INCLS: 424/471.000; 604/891.100; 623/001.440
NCL NCLM: 623/001.420; 424/471.000
NCLS: 424/471.000; 604/891.100; 623/001.440; 514/449.000
IC IPCI A61K0031-337 [ICM,7]; A61K0009-24 [ICS,7]
IPCI-2 A61F0002-06 [I,A]
IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61F0002-00 [N,C*];
A61F0002-00 [N,A]; A61F0002-24 [N,C*]; A61F0002-24 [N,A];
A61F0002-82 [N,C*]; A61F0002-82 [N,A]; A61K0051-12 [I,C*];
A61K0051-12 [I,A]; A61L0027-00 [I,C*]; A61L0027-30 [I,A];
A61L0027-54 [I,A]; A61L0029-00 [I,C*]; A61L0029-08 [I,A];
A61L0029-10 [I,A]; A61L0029-16 [I,A]; A61L0031-08 [I,C*];
A61L0031-08 [I,A]; A61L0031-10 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61L0033-00 [I,C*]; A61L0033-02 [I,A];
A61N0005-10 [N,C*]; A61N0005-10 [N,A]
EXF 623/1.42-1.46; 604/264; 604/265; 604/891.1; 604/892.1; 424/471; 514/449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 378 OF 396 USPAT2 on STN

Full Text

AN 2004:25534 USPAT2
TI Stent device and method
IN Alt, Eckhard, Ottobrunn, GERMANY, FEDERAL REPUBLIC OF
PA Inflow Dynamics Inc., Alexandria, VA, UNITED STATES (U.S. corporation)
PI US 7011680 B2 20060314
AI US 2003-443266 20030522 (10)
RLI Continuation of Ser. No. US 2001-847626, filed on 2 May 2001, Pat. No.
US 6613083, issued on 2 Sep 2003
DT Utility
FS GRANTED
LN.CNT 421
INCL INCLM: 623/001.420
NCL NCLM: 623/001.420
IC IPCI A61F0002-06 [ICM,7]
IPCI-2 A61F0002-06 [I,A]
IPCR A61F0002-06 [I,A]; A61F0002-00 [N,C*]; A61F0002-00 [N,A];
A61F0002-06 [I,C]; A61F0002-82 [I,C*]; A61F0002-82 [I,A];
A61L0031-08 [I,C*]; A61L0031-08 [I,A]; A61L0031-14 [I,C*];
A61L0031-14 [I,A]; A61L0031-16 [I,A]; A61L0033-00 [I,C*];
A61L0033-00 [I,A]
EXF 623/1.42-1.48

L14 ANSWER 379 OF 396 USPAT2 on STN

Full Text

AN 2003:295078 USPAT2
 TI Method for delivering radiation to an intraluminal site in the body
 IN Tam, Lisa A., Lake Forest, CA, United States
 Trauthen, Brett A., Newport Beach, CA, United States
 PA Endologix, Inc., Irvine, CA, United States (U.S. corporation)
 PI US 6685618 B2 20040203
 AI US 2001-944649 20010831 (9)
 RLI Division of Ser. No. US 1999-256337, filed on 19 Feb 1999, now patented,
 Pat. No. US 6287249 Continuation-in-part of Ser. No. US 1998-25921,
 filed on 19 Feb 1998, now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 1797
 INCL INCLM: 600/003.000
 NCL NCLM: 600/003.000
 IC [7]
 ICM A61N005-00
 IPCI A61N0005-00 [ICM, 7]
 IPCI-2 A61N0005-00 [ICM, 7]
 IPCR A61F0002-06 [N,C*]; A61F0002-06 [N,A]; A61F0002-82 [N,C*];
 A61F0002-82 [N,A]; A61K0051-12 [I,C*]; A61K0051-12 [I,A];
 A61N0005-10 [I,C*]; A61N0005-10 [I,A]; C04B0028-00 [I,C*];
 C04B0028-02 [I,A]; G21G0004-00 [I,C*]; G21G0004-06 [I,A]
 EXF 600/1-8; 604/19; 604/53; 604/104; 604/106-107; 604/202; 606/194

L14 ANSWER 380 OF 396 USPAT2 on STN

Full Text

AN 2003:201799 USPAT2
 TI System method and apparatus for localized heating of tissue
 IN Eggers, Philip E., Dublin, OH, UNITED STATES
 Ridihalgh, John L., Columbus, OH, UNITED STATES
 PA Calfacion Corporation, Dublin, OH, UNITED STATES (U.S. corporation)
 PI US 6993394 B2 20060131
 AI US 2002-246347 20020918 (10)
 RLI Continuation-in-part of Ser. No. US 2002-201353, filed on 23 Jul 2002,
 ABANDONED
 PRAI US 2002-349593P 20020118 (60)
 DT Utility
 FS GRANTED
 LN.CNT 5280
 INCL INCLM: 607/103.000
 INCLS: 623/001.150
 NCL NCLM: 607/103.000; 607/096.000
 NCLS: 623/001.150
 IC IPCI A61F0007-00 [ICM, 7]; A61F0007-12 [ICS, 7]
 IPCI-2 A61F0002-00 [I,A]
 IPCR A61B0017-00 [N,C*]; A61B0017-00 [N,A]; A61B0017-22 [N,C*];
 A61B0017-22 [N,A]; A61B0018-04 [I,C*]; A61B0018-04 [I,A];
 A61B0018-18 [N,C*]; A61B0018-18 [N,A]; A61F0007-12 [I,C*];
 A61F0007-12 [I,A]; A61N0007-00 [N,C*]; A61N0007-02 [N,A];
 A61F0002-00 [I,A]; A61F0002-00 [I,C]
 EXF 623/1.15; 623/1.2; 623/1.42-1.43; 607/96; 607/103
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 381 OF 396 USPAT2 on STN

Full Text

AN 2003:200432 USPAT2
 TI Medical articles having enzymatic surfaces for localized therapy
 IN Shepard, Douglas C., Mansfield, MA, UNITED STATES
 PA Boston Scimed, Inc., Maple Grove, MN, UNITED STATES (U.S. corporation)
 PI US 7407668 B2 20080805
 AI US 2002-57596 20020124 (10)
 DT Utility
 FS GRANTED
 LN.CNT 477
 INCL INCLM: 424/422.000
 INCLS: 424/423.000; 424/426.000; 424/484.000; 424/447.000; 530/402.000;
 604/264.000; 604/890.100; 604/891.100
 NCL NCLM: 424/422.000; 424/094.400
 NCLS: 424/423.000; 424/426.000; 424/447.000; 424/484.000; 530/402.000;
 604/264.000; 604/890.100; 604/891.100; 424/094.600; 424/094.610

IC IPCI A61K0038-44 [ICM,7]; A61K0038-46 [ICS,7]; A61K0038-47 [ICS,7];
A61K0038-43 [ICS,7,C*]
IPCI-2 A61F0013-00 [I,A]; A61L0015-16 [I,A]; A61M0005-00 [I,A];
A61K0009-22 [I,A]
IPCR A61B0017-00 [I,C*]; A61B0017-00 [I,A]; A61F0013-00 [I,C];
A61F0013-00 [I,A]; A61F0002-82 [I,C*]; A61F0002-84 [I,A];
A61K0009-22 [I,C]; A61K0009-22 [I,A]; A61L0015-16 [I,C];
A61L0015-16 [I,A]; A61L0015-38 [I,A]; A61L0027-00 [I,C*];
A61L0027-22 [I,A]; A61L0029-00 [I,C*]; A61L0029-00 [I,A];
A61L0031-00 [I,C*]; A61L0031-00 [I,A]; A61M0005-00 [I,C];
A61M0005-00 [I,A]; A61M0025-00 [I,C*]; A61M0025-00 [I,A];
A61M0025-01 [I,C*]; A61M0025-01 [I,A]; C12N0011-00 [I,C*];
C12N0011-00 [I,A]

EXF 424/422-433; 424/484-488; 530/402; 604/264; 604/890.1; 604/891.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 382 OF 396 USPAT2 on STN

Full Text

AN 2003:195442 USPAT2
TI Stent for angioplasty and a production process therefor
IN Vallana, Franco, Turin, ITALY
Chinaglia, Benito, Turin, ITALY
Curcio, Maria, Saluggia, ITALY
Rolando, Giovanni, Chivasso, ITALY
PA Sorin Biomedica Cardio S.p.A., Saluggia, ITALY (non-U.S. corporation)
PI US 6645243 B2 20031111
AI US 1998-4376 19980108 (9)
PRAI IT 1997-T012 19970109
DT Utility
FS GRANTED
LN.CNT 308
INCL INCLM: 623/001.460
INCLS: 623/001.150; 623/001.440; 600/003.000
NCL NCLM: 623/001.460; 623/001.100
NCLS: 600/003.000; 623/001.150; 623/001.440; 623/001.340
IC [7]
ICM A61F002-06
ICS A61N005-00
IPCI A61F0002-06 [ICM,7]; A61N0005-00 [ICS,7]
IPCI-2 A61F0002-06 [ICM,7]; A61N0005-00 [ICS,7]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-06 [I,C*];
A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-90 [I,A];
A61N0005-10 [I,C*]; A61N0005-10 [I,A]
EXF 623/1.1; 623/1.15; 623/1.34; 623/1.42; 623/1.44; 623/1.45; 623/1.46;
600/3

L14 ANSWER 383 OF 396 USPAT2 on STN

Full Text

AN 2003:87262 USPAT2
TI EPTFE covering for endovascular prostheses and method of manufacture
IN Hill, Jason Peter, Brooklyn Park, MN, United States
Sogard, David John, Edina, MN, United States
Tseng, David, Santa Rosa, CA, United States
PA SciMed Life Systems, Inc., Maple Grove, MN, United States (U.S.
corporation)
PI US 6827737 B2 20041207
AI US 2001-962062 20010925 (9)
DT Utility
FS GRANTED
LN.CNT 1055
INCL INCLM: 623/001.400
INCLS: 623/001.130
NCL NCLM: 623/001.400; 623/001.150
NCLS: 623/001.130; 424/424.000; 623/001.420
IC [7]
ICM A61B017-00
IPCI A61F0002-06 [ICM,7]
IPCI-2 A61B0017-00 [ICM,7]
IPCR A61F0002-82 [I,C*]; A61F0002-84 [I,A]; A61F0002-00 [N,C*];
A61F0002-00 [N,A]; A61F0002-06 [I,C*]; A61F0002-06 [I,A]
EXF 606/191; 606/192; 606/194; 606/198; 623/1.12; 623/1.13; 623/1.14;
623/1.15; 623/1.23; 623/1.36; 623/1.38; 623/1.39; 623/1.4; 623/1.42;

623/1.43; 623/1.44; 623/1.45; 623/1.46; 623/1.47; 623/1.48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 384 OF 396 USPAT2 on STN

Full Text

AN 2003:38216 USPAT2
TI Use of rhein or diacerhein compounds for the treatment or prevention of
vascular diseases
IN Cruz, Tony, Toronto, CANADA
Pastrak, Aleksandra, Toronto, CANADA
PA Transition Therapeutics Inc., Toronto, CANADA (non-U.S. corporation)
PI US 6797727 B2 20040928
AI US 2002-196742 20020715 (10)
PRAI US 2001-306111P 20010716 (60)
DT Utility
FS GRANTED
LN.CNT 645
INCL INCLM: 514/510.000
INCLS: 514/548.000
NCL NCLM: 514/510.000; 514/546.000
NCLS: 514/548.000; 514/569.000; 514/621.000; 514/680.000
IC [7]
 ICM A61K031-21
 ICS A61K031-225
 IPCI A61K031-22 [ICM,7]; A61K031-21 [ICM,7,C*]; A61K031-192
 [ICS,7]; A61K031-185 [ICS,7,C*]; A61K031-165 [ICS,7];
 A61K031-12 [ICS,7]
 IPCI-2 A61K031-21 [ICM,7]; A61K031-225 [ICS,7]; A61K031-21 [ICM,7,C*]
 IPCR A61K031-185 [I,C*]; A61K031-192 [I,A]; A61K031-21 [I,C*];
 A61K031-222 [I,A]
EXF 514/510; 514/548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 385 OF 396 USPAT2 on STN

Full Text

AN 2002:330587 USPAT2
TI Medicated stents for the treatment of vascular disease
IN Roorda, Wouter E., Palo Alto, CA, UNITED STATES
Bhat, Vinayak D., Sunnyvale, CA, UNITED STATES
Mouw, Steven L., Mountain View, CA, UNITED STATES
Hossainy, Syed F. A., Fremont, CA, UNITED STATES
Wu, Steven Z., Santa Clara, CA, UNITED STATES
Sanders Millare, Deborra, San Jose, CA, UNITED STATES
PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, UNITED STATES
 (U.S. corporation)
PI US 7651695 B2 20100126
AI US 2001-860384 20010518 (9)
DT Utility
FS GRANTED
LN.CNT 906
INCL INCLM: 424/423.000
INCLS: 623/001.420
NCL NCLM: 604/523.000
NCLS: 424/423.000
IC IPCI A61M0025-00 [ICM,7]
 IPCI-2 A61F0002-00 [I,A]; A61F0002-06 [I,A]
 IPCR A61L0031-08 [I,C*]; A61L0031-10 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]
EXF 424/423; 623/1.42-1.48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 386 OF 396 USPAT2 on STN

Full Text

AN 2002:314375 USPAT2
TI Methods for inhibiting macrophage colony stimulating factor and
c-FMS-dependent cell signaling
IN Rajavashisth, Tripathi, 15203 Florwood Ave., El Camino Village, CA,
UNITED STATES 90260
PI US 7247618 B2 20070724
AI US 2002-94365 20020308 (10)
PRAI US 2001-287426P 20010430 (60)
DT Utility

FS GRANTED
 LN.CNT 1529
 INCL INCLM: 514/044.000
 INCLS: 536/023.100; 536/024.300; 536/024.330; 536/024.500
 NCL NCLM: 514/044.000A; 424/093.200
 NCLS: 536/023.100; 536/024.300; 536/024.330; 536/024.500; 435/456.000;
 514/044.000R
 IC IPCI A61K0048-00 [ICM,7]; C12N0015-86 [ICS,7]
 IPCI-2 A61K0031-70 [I,A]; A01N0043-04 [I,A]; A01N0043-02 [I,C*];
 C07H0021-02 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]
 IPCR A61K0031-70 [I,C]; A61K0031-70 [I,A]; A01N0043-02 [I,C];
 A01N0043-04 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A];
 A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61K0048-00 [I,C*];
 A61K0048-00 [I,A]; A61P0007-00 [I,C*]; A61P0007-12 [I,A];
 A61P0009-00 [I,C*]; A61P0009-10 [I,A]; A61P0019-00 [I,C*];
 A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-28 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; C07H0021-00 [I,C];
 C07H0021-02 [I,A]; C07H0021-04 [I,A]; C12N0015-11 [I,C*];
 C12N0015-11 [I,A]; C12N0015-19 [I,C*]; C12N0015-27 [I,A];
 C12N0015-861 [I,C*]; C12N0015-861 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 387 OF 396 USPAT2 on STN

Full Text

AN 2002:295551 USPAT2
 TI Stent device and method
 IN Alt, Eckhard, Eichendorffstr. 52, Ottobrunn, GERMANY, FEDERAL REPUBLIC
 OF 85521
 PI US 6613083 B2 20030902
 AI US 2001-847626 20010502 (9)
 DT Utility
 FS GRANTED
 LN.CNT 416
 INCL INCLM: 623/001.420
 NCL NCLM: 623/001.420
 IC [7]
 ICM A61F002-06
 IPCI A61F0002-06 [ICM,7]
 IPCI-2 A61F0002-06 [ICM,7]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-06 [I,C*];
 A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-82 [I,A];
 A61L0031-08 [I,C*]; A61L0031-08 [I,A]; A61L0031-14 [I,C*];
 A61L0031-14 [I,A]; A61L0031-16 [I,A]; A61L0033-00 [I,C*];
 A61L0033-00 [I,A]
 EXP 623/1.38; 623/1.39; 623/1.41; 623/1.42; 623/1.43; 623/1.44; 623/1.45;
 623/1.46; 623/1.47; 623/1.48; 623/23.7-23.76

L14 ANSWER 388 OF 396 USPAT2 on STN

Full Text

AN 2002:288552 USPAT2
 TI Methods and apparatus for a stent having an expandable web structure
 IN Oepen, Randolph Von, Tubingen, GERMANY, FEDERAL REPUBLIC OF
 Seibold, Gerd, Ammerbuch, GERMANY, FEDERAL REPUBLIC OF
 PA Jomed GmbH, Rangendingen, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
 corporation)
 PI US 6682554 B2 20040127
 AI US 2000-742144 20001219 (9)
 RLI Continuation-in-part of Ser. No. US 582318
 PRAI DE 1998-19840645 19980905
 DT Utility
 FS GRANTED
 LN.CNT 628
 INCL INCLM: 623/001.150
 INCLS: 623/001.170; 623/001.200
 NCL NCLM: 623/001.150
 NCLS: 623/001.170; 623/001.200
 IC [7]
 ICM A61F002-06
 IPCI A61F0002-06 [ICM,7]
 IPCI-2 A61F0002-06 [ICM,7]
 IPCR A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-82 [I,C*];
 A61F0002-90 [I,A]

EXF 623/1.15; 623/1.16; 623/1.17; 623/1.2; 623/1.13; 606/194; 606/195;
606/191; 606/198

L14 ANSWER 389 OF 396 USPAT2 on STN

Full Text

AN 2002:244023 USPAT2
TI Stent for neutron capture therapy and method of manufacture therefor
IN Lundqvist, Hans, Uppsala, SWEDEN
PA Abbott Laboratories Vascular Entities Limited, Galway, IRELAND (non-U.S.
corporation)
PI US 7022136 B2 20060404
AI US 2001-16044 20011211 (10)
DT Utility
FS GRANTED
LN.CNT 382
INCL INCLM: 623/001.420
INCLS: 600/002.000; 600/003.000
NCL NCLM: 623/001.420; 623/001.150
NCLS: 600/002.000; 600/003.000
IC IPCI A61F0002-06 [ICM,7]
IPCI-2 A61F0002-06 [I,A]
IPCR A61F0002-06 [I,A]; A61F0002-00 [N,C*]; A61F0002-00 [N,A];
A61F0002-06 [I,C]; A61F0002-82 [N,C*]; A61F0002-82 [N,A];
A61K0041-00 [I,C*]; A61K0041-00 [I,A]; A61N0005-10 [I,C*];
A61N0005-10 [I,A]; G21G004-00 [I,C*]; G21G004-08 [I,A]
EXF 623/1.15; 623/1.42-1.46; 600/1-8

L14 ANSWER 390 OF 396 USPAT2 on STN

Full Text

AN 2002:236498 USPAT2
TI Stent and method for drug delivery from stents
IN Daum, Wolfgang, Groton, MA, UNITED STATES
Anderson, Monica L.B., Plymouth, MN, UNITED STATES
Mazzocchi, Rudy A., Indian Harbour Beach, FL, UNITED STATES
PI US 20050278014 A9 20051215
AI US 2002-78622 A1 20020219 (10)
RLI Continuation-in-part of Ser. No. US 2002-44475, filed on 10 Jan 2002,
GRANTED, Pat. No. US 6786904
PRAI US 2001-273850P 20010307 (60)
DT Utility
FS APPLICATION
LN.CNT 446
INCL INCLM: 623/001.150
INCLS: 623/001.420; 604/891.100
NCL NCLM: 623/001.150
NCLS: 604/891.100; 623/001.420
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]
IPCI-2 A61F0002-06 [ICM,7]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-06 [I,C*];
A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-82 [I,A];
A61L0031-14 [I,C*]; A61L0031-16 [I,A]; A61M0025-00 [N,C*];
A61M0025-00 [N,A]

L14 ANSWER 391 OF 396 USPAT2 on STN

Full Text

AN 2002:228637 USPAT2
TI Diffusion barrier layer for implantable devices
IN Pacetti, Stephen D., San Jose, CA, United States
Hossainy, Syed F. A., Fremont, CA, United States
PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, United States
(U.S. corporation)
PI US 6663662 B2 20031216
AI US 2000-750515 20001228 (9)
DT Utility
FS GRANTED
LN.CNT 1827
INCL INCLM: 623/001.130
INCLS: 623/001.440; 623/001.420
NCL NCLM: 623/001.130; 623/001.460
NCLS: 623/001.420; 623/001.440

IC [7]
 ICM A61F002-06
 IPCI A61F0002-06 [ICM, 7]
 IPCI-2 A61F0002-06 [ICM, 7]
 IPCR A61F0002-06 [I,C*]; A61F0002-06 [I,A]
 EXF 623/1.39; 623/1.4; 623/1.42; 623/1.43-1.48

L14 ANSWER 392 OF 396 USPAT2 on STN
Full Text
 AN 2002:227726 USPAT2
 TI Methods of forming a coating for a prosthesis
 IN Harish, Sameer, Fremont, CA, United States
 Wu, Steven, Santa Clara, CA, United States
 Sanders Millare, Deborra, San Jose, CA, United States
 Guruwaiya, Judy, San Jose, CA, United States
 Facetti, Stephen, San Jose, CA, United States
 Hossainy, Syed Faiyaz Ahmed, Fremont, CA, United States
 PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, United States
 (U.S. corporation)
 PI US 6503556 B2 20030107
 AI US 2000-751691 20001228 (9)
 DT Utility
 FS GRANTED
 LN.CNT 625
 INCL INCLM: 427/002.240
 INCLS: 427/002.250; 427/002.280; 427/002.300; 427/553.000; 427/554.000;
 427/555.000; 427/556.000; 427/258.000; 427/261.000; 427/287.000;
 427/407.100; 427/409.000
 NCL NCLM: 427/002.240
 NCLS: 427/002.250; 427/002.280; 427/002.300; 427/258.000; 427/261.000;
 427/287.000; 427/407.100; 427/409.000; 427/553.000; 427/554.000;
 427/555.000; 427/556.000
 IC [7]
 ICM B05D001-36
 ICS B05D003-06; B05D007-20; A61L027-00; A61L033-10
 IPCI A61L0002-00 [ICM, 7]; B05D0003-00 [ICS, 7]
 IPCI-2 B05D0001-36 [ICM, 7]; B05D0003-06 [ICS, 7]; B05D0007-20 [ICS, 7];
 A61L0027-00 [ICS, 7]; A61L0033-10 [ICS, 7]; A61L0033-00 [ICS, 7,C*]
 IPCR A61L0031-08 [I,C*]; A61L0031-10 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]
 EXF 427/2.24; 427/2.25; 427/2.28; 427/2.3; 427/2.31; 427/553; 427/554;
 427/555; 427/556; 427/258; 427/261; 427/287; 427/407.1; 427/409
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 393 OF 396 USPAT2 on STN
Full Text
 AN 2002:119346 USPAT2
 TI Controlled delivery of therapeutic agents by insertable medical devices
 IN Li, Weiping, Salt Lake City, UT, UNITED STATES
 Mao, Hui-Quan, Singapore, SINGAPORE
 Leong, Kam W., Ellicott City, MD, UNITED STATES
 PA Boston Scientific Scimed, Inc., Maple Grove, MN, UNITED STATES (U.S.
 corporation)
 PI US 6899731 B2 20050531
 AI US 2001-750779 20010102 (9)
 PRAI US 1999-173743P 19991230 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1041
 INCL INCLM: 623/001.420
 INCLS: 514/044.000; 435/320.100
 NCL NCLM: 623/001.420; 424/424.000
 NCLS: 435/320.100; 514/044.000R; 604/095.030
 IC [7]
 ICM A61F002-06
 ICS A61K048-00
 IPCI A61M0037-00 [ICM, 7]
 IPCI-2 A61F0002-06 [ICM, 7]; A61K0048-00 [ICS, 7]
 IPCR A61L0029-00 [I,C*]; A61L0029-16 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]
 EXF 423/320.1; 435/455; 435/320.1; 514/44; 514/2; 424/486; 424/93.2;
 623/1.42; 623/1; 604/51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 394 OF 396 USPAT2 on STN

Full Text

AN 2002:17266 USPAT2
TI Nitrosated and nitrosylated taxanes, compositions and methods of use
IN Garvey, David S., Dover, MA, United States
Letts, L. Gordon, Dover, MA, United States
Lin, Chia-En, Burlington, MA, United States
Richardson, Stewart K., Tolland, CT, United States
Wang, Tiansheng, Concord, MA, United States
PA NitroMed, Inc., Bedford, MA, United States (U.S. corporation)
PI US 6656966 B2 20031202
AI US 2001-886494 20010622 (9)
PRAI US 2000-213294P 20000622 (60)
US 2000-226090P 20000818 (60)
DT Utility
FS GRANTED
LN.CNT 3481
INCL INCLM: 514/449.000
INCLS: 549/510.000; 549/511.000
NCL NCLM: 514/449.000; 514/044.000A
NCLS: 549/510.000; 549/511.000; 977/775.000; 977/907.000; 977/915.000;
977/926.000; 424/130.100; 514/171.000; 514/444.000; 549/060.000;
549/472.000
IC [7]
ICM A61K031-337
ICS C07D305-14
IPCI A61K0048-00 [ICM,7]; A61K0039-395 [ICS,7]; A61K0031-381 [ICS,7];
A61K0031-337 [ICS,7]; C07D0035-14 [ICS,7]; C07D0049-02 [ICS,7];
C07D0047-02 [ICS,7]
IPCI-2 A61K0031-337 [ICM,7]; C07D0305-14 [ICS,7]; C07D0305-00 [ICS,7,C*]
IPCR A61K0031-335 [I,C*]; A61K0031-335 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]; A61K0047-48 [I,C*]; A61K0047-48 [I,A];
C07D0305-00 [I,C*]; C07D0305-14 [I,A]; C07D0409-00 [I,C*];
C07D0409-12 [I,A]
EXF 549/510; 549/511; 514/449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 395 OF 396 USPAT2 on STN

Full Text

AN 2002:16657 USPAT2
TI Superoxide dismutase or superoxide dismutase mimic coating for an
intracorporeal medical device
IN Michal, Eugene T., San Francisco, CA, United States
Buchko, Christopher J., Redwood City, CA, United States
Kilpatrick, Deborah L., Mountain View, CA, United States
Bigus, Stephen J., San Jose, CA, United States
PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, United States
(U.S. corporation)
PI US 6541116 B2 20030401
AI US 2001-827977 20010406 (9)
RLI Continuation-in-part of Ser. No. US 1999-240914, filed on 29 Jan 1999,
now patented, Pat. No. US 6287285 Continuation-in-part of Ser. No. US
1998-16694, filed on 30 Jan 1998, now patented, Pat. No. US 6221425
DT Utility
FS GRANTED
LN.CNT 1404
INCL INCLM: 428/420.000
INCLS: 428/425.900; 428/473.500; 428/413.000; 428/500.000; 428/524.000;
623/001.110; 623/001.440; 623/001.460; 623/001.490; 623/001.390;
623/926.000; 623/023.640; 623/023.700; 604/507.000; 604/508.000
NCL NCLM: 428/420.000; 427/002.100
NCLS: 428/413.000; 428/425.900; 428/473.500; 428/500.000; 428/524.000;
604/507.000; 604/508.000; 623/001.110; 623/001.390; 623/001.440;
623/001.460; 623/001.490; 623/023.640; 623/023.700; 623/926.000;
606/192.000
IC [7]
ICM B32B007-04
IPCI A61L0002-00 [ICM,7]; B05D0003-00 [ICS,7]; A61M0029-00 [ICS,7]
IPCI-2 B32B007-04 [ICM,7]
IPCR A61L0029-00 [I,C*]; A61L0029-04 [I,A]; A61L0029-08 [I,A];

A61L0031-04 [I,C*]; A61L0031-04 [I,A]; A61L0031-08 [I,C*];
A61L0031-10 [I,A]
EXF 428/420; 428/425.9; 428/473.5; 428/413; 428/500; 428/524; 623/1.44;
623/1.11; 623/1.46; 623/1.49; 623/1.39; 623/926; 623/23.64; 623/23.7;
623/2.42; 604/507; 604/508
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 396 OF 396 USPAT2 on STN

Full Text

AN 2001:145332 USPAT2
TI Ethylene vinyl alcohol composition and coating
IN Chen, Yung-Ming, Cupertino, CA, United States
Shah, Ashok, San Jose, CA, United States
Bhat, Vinayak D., Sunnyvale, CA, United States
Hossainy, Syed F. A., Fremont, CA, United States
Mirzaee, Daryush, Sunnyvale, CA, United States
Mandrusov, Evgenia, Campbell, CA, United States
Sanders-Millare, Deborra, San Jose, CA, United States
Guruwaiya, Judy A., San Jose, CA, United States
PA Advanced Cardiovascular Systems, Inc., Santa Clara, CA, United States
(U.S. corporation)
PI US 6759054 B2 20040706
AI US 2000-750655 20001228 (9)
RLI Continuation-in-part of Ser. No. US 2000-621123, filed on 21 Jul 2000
Continuation-in-part of Ser. No. US 2000-540242, filed on 31 Mar 2000
Continuation-in-part of Ser. No. US 1999-470559, filed on 23 Dec 1999
Continuation-in-part of Ser. No. US 1999-390855, filed on 3 Sep 1999
Continuation-in-part of Ser. No. US 1999-390069, filed on 3 Sep 1999
DT Utility
FS GRANTED
LN.CNT 974
INCL INCLM: 424/423.000
INCLS: 424/426.000; 428/213.000; 428/387.000; 514/772.300
NCL NCLM: 424/423.000; 523/121.000
NCLS: 424/426.000; 428/213.000; 428/387.000; 514/772.300; 427/002.130
IC [7]
 ICM A61K009-00
 IPCI C08K0003-00 [ICM, 7]; B05D0003-00 [ICS, 7]
 IPCI-2 A61K009-00 [ICM, 7]
 IPCR A61L0027-00 [I,C*]; A61L0027-34 [I,A]; A61L0027-54 [I,A];
 A61L0029-00 [I,C*]; A61L0029-08 [I,A]; A61L0029-16 [I,A];
 A61L0031-08 [I,C*]; A61L0031-10 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61L0033-00 [I,A]; A61L0033-00 [I,C*]
EXF 424/423; 424/426; 514/772.3; 428/213; 428/387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:43:35 ON 17 FEB 2010)

FILE 'REGISTRY' ENTERED AT 18:43:42 ON 17 FEB 2010

 E CLOTRIMAZOLE/CN

L1 1 S E3
L2 E TRAM 34/CN
L3 1 S E3

FILE 'CA' ENTERED AT 18:45:01 ON 17 FEB 2010

L3 33 S L2

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 18:51:17 ON 17 FEB 2010

L4 6 S L2
L5 47024 S (STENOSIS OR RESTENOSIS)
L6 7005 S (STENOSIS OR RESTENOSIS)/CLM
L7 27185 S (IMPLANT? AND STENT?)
L8 4601 S (IMPLANT? AND STENT?)/CLM
L9 13468 S L5 AND L7
L10 620 S L6 AND L8
L11 1723144 S (COAT?)
L12 454731 S (COAT?)/CLM
L13 10648 S L9 AND L11
L14 396 S L10 AND L12

L15 5721 S (CLOTRIMAZOLE)
L16 673 S (CLOTRIMAZOLE)/CLM
L17 269 S L13 AND L15
L18 2 S L14 AND L16

=> s (artery)
L19 89371 (ARTERY)

=> s (artery)/clm
L20 9657 (ARTERY)/CLM

=> s l13 and l19
L21 7409 L13 AND L19

=> s l14 and l20
L22 52 L14 AND L20

=> d 1-52

L22 ANSWER 1 OF 52 USPATFULL on STN

Full Text

AN 2009:320611 USPATFULL
TI POLYMER COMPOSITIONS, COATINGS AND DEVICES, AND METHODS OF MAKING AND
USING THE SAME
IN Meyerhoff, Mark E., Ann Arbor, MI, UNITED STATES
Cha, Wansik, Ann Arbor, MI, UNITED STATES
Hwang, Sang-Yeul, Ann Arbor, MI, UNITED STATES
Reynolds, Melissa M., Ann Arbor, MI, UNITED STATES
PA THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI, UNITED STATES
(U.S. corporation)
MICHIGAN CRITICAL CARE CONSULTANTS, INC. (MC3), Ann Arbor, MI, UNITED
STATES (U.S. corporation)
PI US 20090287072 A1 20091119
AI US 2006-95656 A1 20061201 (12)
WO 2006-US46013 20061201
PCT 371 date 20090311
PRAI US 2005-741601P 20051202 (60)
DT Utility
FS APPLICATION
LN.CNT 1675
INCL INCLM: 600/345.000
INCLS: 523/112.000; 424/424.000; 604/502.000
NCL NCLM: 600/345.000
NCLS: 424/424.000; 523/112.000; 604/502.000
IC IPCI A61M0037-00 [I,A]; A61L0027-34 [I,A]; A61L0027-54 [I,A];
A61L0027-00 [I,C*]; A61P0009-00 [I,A]; A61B0005-1473 [I,A];
A61B0005-145 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 2 OF 52 USPATFULL on STN

Full Text

AN 2009:319417 USPATFULL
TI IMPLANTABLE MEDICAL DEVICES AND COATINGS THEREFOR COMPRISING BLOCK
COPOLYMERS OF POLY(ETHYLENE GLYCOL) AND A POLY(LACTIDE-GLYCOLIDE)
IN LIM, FLORENCIA, Union City, CA, UNITED STATES
Trollsaas, Mikael O., San Jose, CA, UNITED STATES
Ngo, Michael H., San Jose, CA, UNITED STATES
Hu, Jie, Sunnyvale, CA, UNITED STATES
Hossainy, Syed F. A., Fremont, CA, UNITED STATES
Sherman, David J., Tarzana, CA, UNITED STATES
PA Abbott Cardiovascular Systems Inc., Santa Clara, CA, UNITED STATES (U.S.
corporation)
PI US 20090285873 A1 20091119
AI US 2009-484951 A1 20090615 (12)
RLI Continuation-in-part of Ser. No. US 2008-106212, filed on 18 Apr 2008,
PENDING
DT Utility
FS APPLICATION
LN.CNT 1235
INCL INCLM: 424/423.000
INCLS: 514/294.000
NCL NCLM: 424/423.000

NCLS: 514/294.000
IC IPCI A61F0002-00 [I,A]; A61K0031-436 [I,A]; A61K0031-4353 [I,C*];
A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 3 OF 52 USPATFULL on STN

Full Text

AN 2009:309507 USPATFULL
TI System for monitoring the physiologic parameters of patients with congestive heart failure
IN Najafi, Nader, Ann Arbor, MI, UNITED STATES
Rich, Collin Anderson, Ypsilanti, MI, UNITED STATES
PA Integrated Sensing Systems, Inc., Ypsilanti, MI, UNITED STATES (U.S. corporation)
PI US 7615010 B1 20091110
AI US 2003-677694 20031002 (10)
PRAI US 2002-415537P 20021003 (60)
US 2002-415538P 20021003 (60)
US 2002-416406P 20021007 (60)
US 2002-416407P 20021007 (60)
US 2002-416408P 20021007 (60)
US 2002-416409P 20021007 (60)
DT Utility
FS GRANTED
LN.CNT 765
INCL INCLM: 600/481.000
INCLS: 600/300.000; 600/339.000; 600/485.000; 600/504.000; 600/549.000;
607/005.000; 607/006.000; 607/009.000
NCL NCLM: 600/481.000
NCLS: 600/300.000; 600/339.000; 600/485.000; 600/504.000; 600/549.000;
607/005.000; 607/006.000; 607/009.000
IC IPCI A61B0005-00 [I,A]; A61B0005-02 [I,A]; A61N0001-00 [I,A]
EXF 607/6; 600/300; 600/339; 600/481; 600/485; 600/504; 600/549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 52 USPATFULL on STN

Full Text

AN 2009:281823 USPATFULL
TI METHODS AND DEVICES FOR REDUCING TISSUE DAMAGE AFTER ISCHEMIC INJURY
IN Parker, Theodore L., Danville, CA, UNITED STATES
Nguyen, Thai Minh, Santa Clara, CA, UNITED STATES
Shanley, John F., Emerald Hills, CA, UNITED STATES
Litvack, Frank, Los Angeles, CA, UNITED STATES
PA INNOVATIONAL HOLDINGS LLC., New Brunswick, NJ, UNITED STATES (U.S. corporation)
PI US 20090252778 A1 20091008
AI US 2007-295879 A1 20070405 (12)
WO 2007-US66019 20070405
PRAI US 2006-789340P 20090115 PCT 371 date 20060405 (60)
DT Utility
FS APPLICATION
LN.CNT 1336
INCL INCLM: 424/423.000
INCLS: 514 4; 514/449.000; 514/291.000; 424/400.000
NCL NCLM: 424/423.000
NCLS: 424/400.000; 514/004.000; 514/291.000; 514/449.000
IC IPCI A61F0002-04 [I,A]; A61K0038-28 [I,A]; A61K0031-337 [I,A];
A61K0031-436 [I,A]; A61K0031-4353 [I,C*]; A61K0009-00 [I,A];
IPCR A61F0002-04 [I,C]; A61F0002-04 [I,A]; A61K0009-00 [I,C];
A61K0009-00 [I,A]; A61K0031-337 [I,C]; A61K0031-337 [I,A];
A61K0031-4353 [I,C]; A61K0031-436 [I,A]; A61K0038-28 [I,C];
A61K0038-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 52 USPATFULL on STN

Full Text

AN 2009:151717 USPATFULL
TI Anti-Restenosis Coatings and Uses Thereof
IN Williams, Tong Li, Shrewsbury, MA, UNITED STATES
Wu, Tim, Shrewsbury, MA, UNITED STATES
PA VASOTECH, INC., Lowell, MA, UNITED STATES (U.S. corporation)

PI US 20090136558 A1 20090528
 AI US 2008-209104 A1 20080911 (12)
 RLI Continuation-in-part of Ser. No. US 2005-144917, filed on 6 Jun 2005,
 ABANDONED Continuation-in-part of Ser. No. US 2007-843528, filed on 22
 Aug 2007, PENDING
 PRAI US 2004-578219P 20040608 (60)
 US 2006-823168P 20060822 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1303
 INCL INCLM: 424/423.000
 INCLS: 514/291.000; 514/449.000
 NCL NCLM: 424/423.000
 NCLS: 514/291.000; 514/449.000
 IC IPCI A61F0002-00 [I,A]; A61K0031-4355 [I,A]; A61K0031-4353 [I,C*];
 A61K0031-337 [I,A]
 IPCR A61F0002-00 [I,C]; A61F0002-00 [I,A]; A61K0031-337 [I,C];
 A61K0031-337 [I,A]; A61K0031-4353 [I,C]; A61K0031-4355 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 6 OF 52 USPATFULL on STN

FULL Text

AN 2009:58822 USPATFULL
 TI COATING STENTS WITH CYCLIC RGD PEPTIDES OR MIMETICS
 IN Joner, Michael, Munich, GERMANY, FEDERAL REPUBLIC OF
 Kessler, Horst, Garching, GERMANY, FEDERAL REPUBLIC OF
 Virmani, Renu, Chevy Chase, MD, UNITED STATES
 PI US 20090053280 A1 20090226
 AI US 2008-121568 A1 20080515 (12)
 PRAI US 2007-930208P 20070515 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1148
 INCL INCLM: 424/423.000
 INCLS: 427/022.500; 623/014.600
 NCL NCLM: 424/423.000
 NCLS: 427/002.250; 623/001.460
 IC IPCI A61L0027-54 [I,A]; A61F0002-82 [I,A]; A61L0027-28 [I,A];
 A61L0027-00 [I,C*]
 IPCR A61L0027-00 [I,C]; A61L0027-54 [I,A]; A61F0002-82 [I,C];
 A61F0002-82 [I,A]; A61L0027-28 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 7 OF 52 USPATFULL on STN

FULL Text

AN 2009:53090 USPATFULL
 TI Compounds, Methods And Devices for Inhibiting Neoproliferative Changes
 in Blood Vessel Walls
 IN Koehler, Ralf, Berlin, GERMANY, FEDERAL REPUBLIC OF
 Wulff, Heike, Davis, CA, UNITED STATES
 Hoyer, Joachim, Berlin, GERMANY, FEDERAL REPUBLIC OF
 Chandy, K. George, Laguna Beach, CA, UNITED STATES
 PI US 20090048270 A1 20090219
 AI US 2003-533060 A1 20031030 (10)
 WO 2003-US34837 20031030
 20070312 PCT 371 date
 PRAI US 2002-422712P 20021030 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1621
 INCL INCLM: 514/256.000
 INCLS: 514/648.000; 514/617.000; 514/352.000; 514/413.000; 514/370.000;
 514/381.000; 514/394.000; 514/407.000
 NCL NCLM: 514/256.000
 NCLS: 514/352.000; 514/370.000; 514/381.000; 514/394.000; 514/407.000;
 514/413.000; 514/617.000; 514/648.000
 IC IPCI A61K0031-505 [I,A]; A61K0031-136 [I,A]; A61K0031-165 [I,A];
 A61K0031-426 [I,A]; A61K0031-4184 [I,A]; A61K0031-4164 [I,C*];
 A61P0009-00 [I,A]; A61K0031-415 [I,A]; A61K0031-41 [I,A];
 A61K0031-4035 [I,A]; A61K0031-403 [I,C*]; A61K0031-44 [I,A]
 IPCR A61K0031-505 [I,C]; A61K0031-505 [I,A]; A61K [I,S]; A61K0031-136
 [I,C]; A61K0031-136 [I,A]; A61K0031-165 [I,C]; A61K0031-165

[I,A]; A61K0031-403 [I,C]; A61K0031-4035 [I,A]; A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-415 [I,C]; A61K0031-415 [I,A]; A61K0031-4164 [I,C]; A61K0031-4184 [I,A]; A61K0031-426 [I,C]; A61K0031-426 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0009-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 8 OF 52 USPATFULL on STN

Full Text

AN 2009:31544 USPATFULL
TI MEDICAL DEVICES INCORPORATING COLLAGEN INHIBITORS
IN Sullivan, Christopher A., Winston-Salem, NC, UNITED STATES
Hodges, Steve J., Winston-Salem, NC, UNITED STATES
PA Wake Forest University Health Science, Winston-Salem, NC, UNITED STATES
(U.S. corporation)
PI US 20090028914 Al 20090129
AI US 2008-130614 Al 20080530 (12)
RLI Continuation-in-part of Ser. No. US 2007-948294, filed on 30 Nov 2007,
PENDING
PRAI US 2006-868217P 20061201 (60)
DT Utility
FS APPLICATION
LN.CNT 1700
INCL INCLM: 424/402.000
INCLS: 424/423.000; 424/426.000; 514/033.000
NCL NCLM: 424/402.000
NCLS: 424/423.000; 424/426.000; 514/033.000
IC IPCI A61K0002-00 [I,A]; A61K0031-7028 [I,A]
IPCR A61K0002-00 [I,C]; A61F0002-00 [I,A]; A61K0031-7028 [I,C];
A61K0031-7028 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 9 OF 52 USPATFULL on STN

Full Text

AN 2009:24667 USPATFULL
TI Peptides Effective in the Treatment of Tumors and Other Conditions
Requiring the Removal or Destruction of Cells
IN Averback, Paul, Beaconsfield, CANADA
Gemmell, Jack, Mississauga, CANADA
PA Nymox Pharmaceutical Corporation, St. Laurent, CANADA (non-U.S.
corporation)
PI US 20090022743 Al 20090122
AI US 2008-171462 Al 20080711 (12)
RLI Division of Ser. No. US 2004-920313, filed on 12 Oct 2004, Pat. No. US
7408021 Continuation of Ser. No. US 2002-294891, filed on 15 Nov 2002,
Pat. No. US 7317077
PRAI US 2001-331477P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 2590
INCL INCLM: 424/178.100
INCLS: 514/013.000
NCL NCLM: 424/178.100
NCLS: 514/013.000
IC IPCI A61K0038-10 [I,A]; A61P0035-00 [I,A]; A61P0017-00 [I,A];
A61P0029-00 [I,A]; A61P0037-00 [I,A]; A61P0003-00 [I,A];
A61K0039-395 [I,A]
IPCR A61K0038-10 [I,C]; A61K0038-10 [I,A]; A61K0038-00 [N,C*];
A61K0038-00 [N,A]; A61K0039-395 [I,C]; A61K0039-395 [I,A];
A61P0003-00 [I,C]; A61P0003-00 [I,A]; A61P0017-00 [I,C];
A61P0017-00 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A];
A61P0035-00 [I,A]; A61P0035-00 [I,A]; A61P0037-00 [I,C];
A61P0037-00 [I,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 10 OF 52 USPATFULL on STN

Full Text

AN 2009:11699 USPATFULL
TI Methods and Devices for Reducing Tissue Damage After Ischemic Injury
IN Parker, Theodore L., Danville, CA, UNITED STATES
Litvack, Frank, Los Angeles, CA, UNITED STATES
PA Conor Medsystems, Inc., Menlo Park, CA, UNITED STATES (U.S. corporation)

PI US 20090010987 A1 20090108
 AI US 2006-555448 A1 20061101 (11)
 PRAI US 2005-733108P 20051102 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 980
 INCL INCLM: 424/423.000
 INCLS: 514 3
 NCL NCLM: 424/423.000
 NCLS: 514/003.000
 IC IPCI A61F0002-01 [I,A]; A61K0038-28 [I,A]; A61P0009-10 [I,A];
 A61P0009-00 [I,C*]
 IPCR A61F0002-01 [I,C]; A61F0002-01 [I,A]; A61K0038-28 [I,C];
 A61K0038-28 [I,A]; A61P0009-00 [I,C]; A61P0009-10 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 11 OF 52 USPATFULL on STN

Full Text

AN 2008:305530 USPATFULL
 TI Furoxan Compounds, Compositions and Methods of Use
 IN Garvey, David S., Dover, MA, UNITED STATES
 Ranatunge, Ramani R., Lexington, MA, UNITED STATES
 PA NITROMED, INC., Lexington, MA, UNITED STATES (U.S. corporation)
 PI US 20080268014 A1 20081030
 AI US 2006-93561 A1 20061116 (12)
 WO 2006-US44680 20061116
 20080513 PCT 371 date
 PRAI US 2005-736871P 20051116 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3207
 INCL INCLM: 424/423.000
 INCLS: 548/125.000; 514/364.000; 514/248.000; 424/718.000
 NCL NCLM: 424/423.000
 NCLS: 424/718.000; 514/248.000; 514/364.000; 548/125.000
 IC IPCI A61K0009-00 [I,A]; C07D0271-08 [I,A]; C07D0271-00 [I,C*];
 A61K0031-4245 [I,A]; A61P0009-00 [I,A]; A61K0031-502 [I,A];
 A61K0033-00 [I,A]
 IPCR A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0031-4245 [I,C];
 A61K0031-4245 [I,A]; A61K0031-502 [I,C]; A61K0031-502 [I,A];
 A61K0033-00 [I,C]; A61K0033-00 [I,A]; A61P0009-00 [I,C];
 A61P0009-00 [I,A]; C07D0271-00 [I,C]; C07D0271-08 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 12 OF 52 USPATFULL on STN

Full Text

AN 2008:239635 USPATFULL
 TI C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
 IN Marx, Steven O., New York, NY, UNITED STATES
 Marks, Andrew R., Larchmont, NY, UNITED STATES
 PA The Trustees of Columbia University, New York City, NY, UNITED STATES (U.S. corporation)
 PI US 20080208326 A1 20080828
 US 7662178 B2 20100216
 AI US 2008-150695 A1 20080429 (12)
 RLI Continuation of Ser. No. US 2002-326936, filed on 20 Dec 2002, Pat. No. US 7364586
 PRAI US 2001-343030P 20011221 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 802
 INCL INCLM: 623/014.600
 INCLS: 623/014.200
 NCL NCLM: 623/001.420
 NCLS: 623/001.430
 IC IPCI A61F0002-06 [I,A]
 IPCI-2 A61F0002-82 [I,A]; A61F0002-00 [I,A]
 IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61L0031-08 [I,C*];
 A61L0031-10 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

L22 ANSWER 13 OF 52 USPATFULL on STN

Full Text

AN 2008:238801 USPATFULL
TI Use of CCN5 for treatment of smooth muscle proliferation disorders
IN Castellot, John, Newton, MA, UNITED STATES
Gray, Mark R., West Roxbury, MA, UNITED STATES
Simon, Amy R., Newton, MA, UNITED STATES
PI US 20080207489 Al 20080828
AI US 2008-70814 Al 20080221 (12)
PRAI US 2007-961859P 20070725 (60)
US 2007-890865P 20070221 (60)
DT Utility
FS APPLICATION
LN.CNT 3095
INCL INCLM: 514 2
INCLS: 514/044.000
NCL NCLM: 514/002.000
NCLS: 514/044.000A
IC IPCI A61K0038-02 [I,A]; A61K0048-00 [I,A]; A61P0035-00 [I,A];
A61P0021-00 [I,A]
IPCR A61K0038-02 [I,C]; A61K0038-02 [I,A]; A61K0048-00 [I,C];
A61K0048-00 [I,A]; A61P0021-00 [I,C]; A61P0021-00 [I,A];
A61P0035-00 [I,C]; A61P0035-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 14 OF 52 USPATFULL on STN

Full Text

AN 2008:196046 USPATFULL
TI Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
IN Stern, David M., Great Neck, NY, UNITED STATES
Schmidt, Ann Marie, Franklin Lakes, NJ, UNITED STATES
Marso, Steven, Shawnee, KS, UNITED STATES
Topol, Eric, Chagrin Falls, OH, UNITED STATES
Lincoff, A. Michael, Orange Village, OH, UNITED STATES
PA The Cleveland Clinic Foundation (U.S. corporation)
The Trustees of Columbia University in the City of New York (U.S. corporation)
PI US 20080171701 Al 20080717
AI US 2007-894809 Al 20070820 (11)
RLI Continuation of Ser. No. US 2000-687528, filed on 13 Oct 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1222
INCL INCLM: 514/012.000
INCLS: 514/044.000; 424/092.000
NCL NCLM: 514/012.000
NCLS: 424/009.200; 514/044.000R
IC IPCI A61K0048-00 [I,A]; A61K0038-17 [I,A]; A61K0049-00 [I,A]
IPCR A61K0048-00 [I,C]; A61K0048-00 [I,A]; A61K0031-00 [I,C*];
A61K0031-00 [I,A]; A61K0038-17 [I,C]; A61K0038-17 [I,A];
A61K0049-00 [I,C]; A61K0049-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 15 OF 52 USPATFULL on STN

Full Text

AN 2008:59038 USPATFULL
TI Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
IN Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopeliano, Angelo George, Whitehouse Station, NJ, UNITED STATES
PI US 20080051883 Al 20080228
AI US 2007-941233 Al 20071116 (11)
RLI Continuation of Ser. No. US 2007-782740, filed on 25 Jul 2007, PENDING
Continuation of Ser. No. US 2006-437572, filed on 19 May 2006, PENDING
Continuation of Ser. No. US 2003-636435, filed on 7 Aug 2003, GRANTED,
Pat. No. US 7056550 Continuation of Ser. No. US 2001-962496, filed on 25 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-675882, filed on 29 Sep 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2353

INCL INCLM: 623/001.420
INCLS: 427/002.250
NCL NCLM: 623/001.420
NCLS: 427/002.250
IC IPCI A61F0002-06 [I,A]; B05D0003-00 [I,A]
IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; B05D0003-00 [I,C];
B05D0003-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 16 OF 52 USPATFULL on STN

Full Text

AN 2008:59037 USPATFULL
TI Medical device for intra-luminal delivery of pharmaceutical agents
IN Rubin, Leo, Suffern, NY, UNITED STATES
PI US 20080051882 AI 20080228
AI US 2005-55465 AI 20050210 (11)
DT Utility
FS APPLICATION
LN.CNT 714
INCL INCLM: 623/014.200
NCL NCLM: 623/001.420
IC IPCI A61F0002-82 [I,A]
IPCR A61F0002-82 [I,C]; A61F0002-82 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 17 OF 52 USPATFULL on STN

Full Text

AN 2007:316266 USPATFULL
TI Medical Devices, Drug Coatings and Methods for Maintaining the Drug
Coatings Thereon
IN Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopelianos, Angelo George, Whitehouse Station, NJ, UNITED STATES
PI US 20070276473 AI 20071129
AI US 2007-782740 AI 20070725 (11)
RLI Continuation of Ser. No. US 2006-437572, filed on 19 May 2006, PENDING
Continuation of Ser. No. US 2003-636435, filed on 7 Aug 2003, GRANTED,
Pat. No. US 7056550 Continuation of Ser. No. US 2001-962496, filed on 25
Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-675882,
filed on 29 Sep 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2353
INCL INCLM: 623/001.420
INCLS: 427/002.250
NCL NCLM: 623/001.420
NCLS: 427/002.250
IC IPCI A61F0002-82 [I,A]
IPCR A61F0002-82 [I,C]; A61F0002-82 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 18 OF 52 USPATFULL on STN

Full Text

AN 2007:308396 USPATFULL
TI Methods and Devices for Reducing Tissue Damage After Ischemic Injury
IN Parker, Theodore L., Danville, CA, UNITED STATES
Nguyen, Thai Minh, Santa Clara, CA, UNITED STATES
Shanley, John F., Redwood City, CA, UNITED STATES
Litvack, Frank, Los Angeles, CA, UNITED STATES
PA Conor Medsystems, LLC., Menlo Park, CA, UNITED STATES (U.S. corporation)
PI US 20070269486 AI 20071122
AI US 2007-696360 AI 20070404 (11)
RLI Continuation-in-part of Ser. No. US 2006-375454, filed on 14 Mar 2006,
PENDING
PRAI US 2005-662040P 20050314 (60)
US 2006-789340P 20060405 (60)
DT Utility
FS APPLICATION
LN.CNT 1342
INCL INCLM: 424/426.000
INCLS: 424/423.000; 514/291.000; 514/004.000; 514/449.000; 514/789.000
NCL NCLM: 424/426.000

IC NCCLS: 424/423.000; 514/004.000; 514/291.000; 514/449.000; 514/789.000
IPCI A61F0002-06 [I,A]; A61K0031-337 [I,A]; A61K0031-4353 [I,A];
A61K0038-28 [I,A]; A61P0009-00 [I,A]
IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61K0031-337 [I,C];
A61K0031-337 [I,A]; A61K0031-4353 [I,C]; A61K0031-4353 [I,A];
A61K0038-28 [I,C]; A61K0038-28 [I,A]; A61P0009-00 [I,C];
A61P0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 19 OF 52 USPATFULL on STN

Full Text

AN 2007:204937 USPATFULL
TI Medical Devices, Drug Coatings and Methods for Maintaining the Drug
Coatings Thereon
IN Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
Roller, Mark B., North Brunswick, NJ, UNITED STATES
Scopelianios, Angelo George, Whitehouse Station, NJ, UNITED STATES
PI US 20070179594 A1 20070802
AI US 2007-735773 A1 20070416 (11)
RLI Continuation of Ser. No. US 2003-636435, filed on 7 Aug 2003, GRANTED,
Pat. No. US 7056550 Continuation of Ser. No. US 2001-962496, filed on 25
Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-675882,
filed on 29 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US
2001-884729, filed on 19 Jun 2001, GRANTED, Pat. No. US 6863685
Continuation-in-part of Ser. No. US 2001-887464, filed on 22 Jun 2001,
PENDING Continuation-in-part of Ser. No. US 2001-850482, filed on 7 May
2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 2357
INCL INCLM: 623/001.420
INCLS: 427/002.240
NCL NCLM: 623/001.420
NCLS: 427/002.240
IC IPCI A61F0002-90 [I,A]; A61F0002-82 [I,C*]; B05D0003-00 [I,A];
A61L0033-00 [I,A]
IPCR A61F0002-82 [I,C]; A61F0002-90 [I,A]; A61L0033-00 [I,C];
A61L0033-00 [I,A]; B05D0003-00 [I,C]; B05D0003-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 20 OF 52 USPATFULL on STN

Full Text

AN 2007:154073 USPATFULL
TI Methods for reducing intimal hyperplasia, smooth muscle cell
proliferation and restenosis in mammals
IN Wu-Wong, Jinshyun R., Libertyville, IL, UNITED STATES
PI US 20070134286 A1 20070614
AI US 2005-292050 A1 20051201 (11)
PRAI US 2004-632555P 20041202 (60)
DT Utility
FS APPLICATION
LN.CNT 1214
INCL INCLM: 424/423.000
INCLS: 514/167.000
NCL NCLM: 424/423.000
NCLS: 514/167.000
IC IPCI A61K0031-59 [I,A]
IPCR A61K0031-59 [I,C]; A61K0031-59 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 21 OF 52 USPATFULL on STN

Full Text

AN 2007:141548 USPATFULL
TI Treatment of Restenosis and Stenosis with Dasatinib
IN Wu, Jie, 9355 Wellington Park Circle, Tampa, FL, UNITED STATES 33647
Chen, Zhengming, 6235 Ashbury Palms Drive, Tampa, FL, UNITED STATES
33647
Bhalla, Kapil N., 6202 S. Russell Street, Tampa, FL, UNITED STATES
33611
PA UNIVERSITY OF SOUTH FLORIDA, Tampa, FL, UNITED STATES, 33612 (U.S.
corporation)
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL,

UNITED STATES, 33612 (U.S. corporation)
PI US 20070123539 Al 20070531
AI US 2006-551116 Al 20061019 (11)
PRAI US 2005-728673P 20051020 (60)
DT Utility
FS APPLICATION
LN.CNT 1118
INCL INCLM: 514/252.190
NCL NCLM: 514/252.190
IC IPCI A61K0031-506 [I,A]
IPCR A61K0031-506 [I,C]; A61K0031-506 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 22 OF 52 USPATFULL on STN
Full Text

AN 2007:109438 USPATFULL
TI System for monitoring conduit obstruction
IN Najafi, Nader, Ann Arbor, MI, UNITED STATES
Rich, Collin Anderson, Ypsilanti, MI, UNITED STATES
Massoud-Ansari, Sonbol, Ann Arbor, MI, UNITED STATES
PA Integrated Sensing Systems, Inc., Ypsilanti, MI, UNITED STATES (U.S.
corporation)
PI US 7211048 B1 20070501
AI US 2003-679916 20031006 (10)
PRAI US 2002-416406P 20021007 (60)
US 2002-416407P 20021007 (60)
US 2002-416408P 20021007 (60)
US 2002-416409P 20021007 (60)
DT Utility
FS GRANTED
LN.CNT 483
INCL INCLM: 600/508.000
INCLS: 600/481.000; 600/483.000; 600/485.000; 600/486.000; 607/060.000;
607/126.000
NCL NCLM: 600/508.000
NCLS: 600/481.000; 600/483.000; 600/485.000; 600/486.000; 607/060.000;
607/126.000
IC IPCI A61B0005-02 [I,A]; A61B0005-04 [I,A]; A61N0001-00 [I,A]
IPCR A61B0005-02 [I,C]; A61B0005-02 [I,A]; A61B0005-04 [I,C];
A61B0005-04 [I,A]; A61N0001-00 [I,C]; A61N0001-00 [I,A]
EXF 600/481; 600/483; 600/485; 600/486; 600/508; 600/513; 600/322; 607/60;
607/126; 128/903

L22 ANSWER 23 OF 52 USPATFULL on STN

Full Text
AN 2006:10579 USPATFULL
TI Nitrosated and nitrosylated compounds, compositions and methods use
IN Earl, Richard A., Westford, MA, UNITED STATES
Earl, Richard A., Westford, MA, UNITED STATES
Garvey, David S., Dover, MA, UNITED STATES
Gaston, Ricky D., Malden, MA, UNITED STATES
Lin, Chia-En, Concord, MA, UNITED STATES
Ranatunge, Ramani R., Lexington, MA, UNITED STATES
Richardson, Stewart K., Tolland, CT, UNITED STATES
Stevenson, Cheri A., Haverhill, MA, UNITED STATES
PA NitroMed, Inc., Lexington, MA, UNITED STATES (U.S. corporation)
PI US 20060009431 Al 20060112
AI US 2005-221901 Al 20050909 (11)
RLI Continuation of Ser. No. WO 2004-US7943, filed on 15 Mar 2004, PENDING
PRAI US 2003-453963P 20030313 (60)
US 2003-482134P 20030625 (60)
DT Utility
FS APPLICATION
LN.CNT 6251
INCL INCLM: 514/171.000
INCLS: 514/509.000
NCL NCLM: 514/171.000
NCLS: 514/509.000
IC IPCI A61K0031-56 [I,A]; A61K0031-21 [I,A]
IPCR A61K0031-56 [I,A]; A61K0031-21 [I,C]; A61K0031-21 [I,A];
A61K0031-56 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 24 OF 52 USPATFULL on STN

Full Text

AN 2005:331266 USPATFULL
TI Treatment and prevention of abnormal cellular proliferation
IN Hales, Charles A., Lincoln, MA, UNITED STATES
Garg, Hari G., Belmont, MA, UNITED STATES
Yu, Lunyin, Allston, MA, UNITED STATES
Linhardt, Robert J., Albany, NY, UNITED STATES
PA The General Hospital Corporation, Boston, MA, UNITED STATES (U.S. corporation)
The University of Iowa Research Foundation, Iowa City, IA, UNITED STATES (U.S. corporation)
PI US 20050288251 A1 20051229
US 7538096 B2 20090526
AI US 2005-82213 A1 20050316 (11)
PRAI US 2004-553800P 20040316 (60)
DT Utility
FS APPLICATION
LN.CNT 1141
INCL INCLM: 514/056.000
NCL NCLM: 514/056.000
NCLS: 514/054.000; 536/021.000
IC [7]
ICM A61K031-727
IPCI A61K0031-727 [ICM,7]; A61K0031-726 [ICM,7,C*]
IPCI-2 A61K0031-727 [I,A]; A61K0031-726 [I,C*]
IPCR A61K0031-726 [I,C]; A61K0031-727 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 25 OF 52 USPATFULL on STN

Full Text

AN 2005:270525 USPATFULL
TI Use of VEGF-C to prevent restenosis
IN Alitalo, Kari, Espoo, FINLAND
Yla-Herttuala, Seppo, Kuopio, FINLAND
Hiltunen, Mikko O., Kuopio, FINLAND
Jeltsch, Markku M., Helsinki, FINLAND
Achen, Marc G., North Melbourne, AUSTRALIA
PA Licentia Ltd, Helsinki, FINLAND (non-U.S. corporation)
Seppo Yla-Herttuala, Kuopio, FINLAND (non-U.S. corporation)
Ludwig Institute of Cancer Research, New York, NY, UNITED STATES (U.S. corporation)
PI US 6958147 B1 20051025
AI US 1999-427657 19991026 (9)
PRAI US 1998-105587P 19981026 (60)
DT Utility
FS GRANTED
LN.CNT 2255
INCL INCLM: 424/093.200
INCLS: 424/093.100; 424/093.210; 435/069.100; 435/320.100; 435/325.000;
435/455.000; 514/044.000; 536/023.100; 536/023.500
NCL NCLM: 424/093.200
NCLS: 424/093.100; 424/093.210; 435/069.100; 435/320.100; 435/325.000;
435/455.000; 514/044.000R; 536/023.100; 536/023.500
IC [7]
ICM A01N063-00
ICS C12P021-06; C12N015-00; A61N043-04; C07H021-02
IPCI A01N0063-00 [ICM,7]; C12P0021-06 [ICS,7]; C12N0015-00 [ICS,7];
A61N0043-04 [ICS,7]; C07H0021-02 [ICS,7]; C07H0021-00 [ICS,7,C*]
IPCR A01N0063-00 [I,C*]; A01N0063-00 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0048-00 [I,C*]; A61K0048-00 [I,A];
C07H0021-00 [I,C*]; C07H0021-02 [I,A]; C07K0014-435 [I,C*];
C07K0014-52 [I,A]; C12N0015-00 [I,C*]; C12N0015-00 [I,A];
C12P0021-06 [I,C*]; C12P0021-06 [I,A]
EXF 424/93.1.; 424/93.2.; 424/93.21.; 424/93.6.; 435/69.1.; 435/320.1.; 435/325;
435/455; 435/328; 514/44; 536/23.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 26 OF 52 USPATFULL on STN

Full Text

AN 2005:241261 USPATFULL
TI Nitrosated and nitrosylated rapamycin compounds, compositions and

methods of use
IN Garvey, David S., Dover, MA, UNITED STATES
PA NitroMed, Inc., Lexington, MA, UNITED STATES (U.S. corporation)
PI US 20050209266 A1 20050922
US 7345053 B2 20080318
AI US 2005-135308 A1 20050524 (11)
RLI Continuation of Ser. No. WO 2003-US39562, filed on 15 Dec 2003, PENDING
PRAI US 2002-433595P 20021216 (60)
US 2003-513215P 20031023 (60)
DT Utility
FS APPLICATION
LN.CNT 2770
INCL INCLM: 514/291.000
INCLS: 540/465.000
NCL NCLM: 514/291.000
NCLS: 540/456.000; 540/465.000
IC [7]
ICM A61K031-4745
IPCI A61K031-4745 [ICM,7]; A61K031-4738 [ICM,7,C*]
IPCI-2 C07D0498-18 [I,A]; C07D0498-00 [I,C*]; A61K031-445 [I,A]
IPCR C07D0498-00 [I,C]; C07D0498-18 [I,A]; A61K031-445 [I,C];
A61K031-445 [I,A]; A61K031-4738 [I,C*]; A61K031-4745 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 27 OF 52 USPATFULL on STN

Full Text

AN 2005:202249 USPATFULL
TI Use of endothelin antagonists to prevent restenosis
IN Carlyle, Wenda, Silverado, CA, UNITED STATES
PI US 20050175667 A1 20050811
AI US 2005-54009 A1 20050208 (11)
PRAI US 2004-543252P 20040210 (60)
DT Utility
FS APPLICATION
LN.CNT 1396
INCL INCLM: 424/423.000
INCLS: 604/500.000; 514/649.000
NCL NCLM: 424/423.000
NCLS: 514/649.000; 604/500.000
IC [7]
ICM A61F002-00
ICS A61M031-00; A61K031-137
IPCI A61F0002-00 [ICM,7]; A61M0031-00 [ICS,7]; A61K0031-137 [ICS,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61K0031-00 [I,C*];
A61K0031-00 [I,A]; A61K0031-137 [I,C*]; A61K0031-137 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 28 OF 52 USPATFULL on STN

Full Text

AN 2005:197456 USPATFULL
TI Heparin stent
IN Harnek, Jan, Malmo, SWEDEN
Zouka, Eftichia-Vassiliki, Malmo, SWEDEN
PA ZOUCAS KIRURGKONSULT AB, 217 73 MALMO, SWEDEN (non-U.S. corporation)
PI US 20050171600 A1 20050804
AI US 2003-484935 A1 20020708 (10)
WO 2002-SE1356 20020708
PRAI SE 2001-2621 20010727
DT Utility
FS APPLICATION
LN.CNT 554
INCL INCLM: 623/001.420
NCL NCLM: 623/001.420
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]
IPCR A61L0031-08 [I,C*]; A61L0031-10 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61L0033-00 [I,C*]; A61L0033-00 [I,A]

L22 ANSWER 29 OF 52 USPATFULL on STN

Full Text

AN 2005:138619 USPATFULL

TI Heterocyclic compounds and methods of making and using thereof
IN Rao, Yeleswarapu Koteswar, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Sharma, Vedula Manohar, Hyderabad, INDIA
Venkateswarlu, Akella, Hyderabad, INDIA
Pillarisetti, Ram, Norcross, GA, UNITED STATES
PI US 20050119269 Al 20050602
US 7456288 B2 20081125
AI US 2004-976284 Al 20041028 (10)
PRAI IN 2003-CH861 20031028
US 2004-610163P 20040915 (60)
DT Utility
FS APPLICATION
LN.CNT 13564
INCL INCLM: 514/251.000
INCLS: 514/262.100; 544/256.000; 544/257.000
NCL NCLM: 546/158.000; 514/251.000
NCLS: 546/157.000; 514/262.100; 544/256.000; 544/257.000
IC [7]
ICM A61K031-525
ICS A61K031-519; C07D487-02; C07D475-02
IPCI A61K0031-525 [ICM,7]; A61K0031-519 [ICS,7]; C07D0487-02 [ICS,7];
C07D0475-00 [ICS,7,C*]; C07D0475-02 [ICS,7]; C07D0475-00
[ICS,7,C*]
IPCI-2 C07D0215-04 [I,A]; C07D0215-00 [I,C*]
IPCR C07D0215-00 [I,C]; C07D0215-04 [I,A]; A61K0031-519 [I,C*];
A61K0031-519 [I,A]; A61K0031-525 [I,A]; C07D0475-00 [I,C*];
C07D0475-02 [I,A]; C07D0487-00 [I,C*]; C07D0487-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 30 OF 52 USPATFULL on STN

Full Text

AN 2005:82540 USPATFULL
TI Medical devices having porous layers and methods for making the same
IN Lye, Whye-Kei, Charlottesville, VA, UNITED STATES
Reed, Michael, Charlottesville, VA, UNITED STATES
Owens, Gary, Earlysille, VA, UNITED STATES
Wamhoff, Brian, Charlottesville, VA, UNITED STATES
Hudson, Matthew, Charlottesville, VA, UNITED STATES
Looi, Karen, Charlottesville, VA, UNITED STATES
PI US 20050070989 Al 20050331
AI US 2004-918853 Al 20040813 (10)
RLI Continuation-in-part of Ser. No. US 2003-713244, filed on 13 Nov 2003,
PENDING
PRAI US 2002-426106P 20021113 (60)
DT Utility
FS APPLICATION
LN.CNT 1870
INCL INCLM: 623/001.400
INCLS: 623/001.420; 424/424.000; 427/002.210; 604/890.100
NCL NCLM: 623/001.400
NCLS: 424/424.000; 427/002.210; 604/890.100; 623/001.420
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]
IPCR A61F0002-06 [I,C*]; A61F0002-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 31 OF 52 USPATFULL on STN

Full Text

AN 2005:44764 USPATFULL
TI Methods for coating stents with DNA and expression of recombinant genes
from DNA coated stents in vivo
IN Nabel, Elizabeth G., Ann Arbor, MI, UNITED STATES
Nabel, Gary J., Ann Arbor, MI, UNITED STATES
Yang, Zhi-yong, Ann Arbor, MI, UNITED STATES
PI US 20050038499 Al 20050217
AI US 2004-946785 Al 20040922 (10)
RLI Division of Ser. No. US 1997-884352, filed on 27 Jun 1997, GRANTED, Pat.
No. US 6818016
DT Utility
FS APPLICATION

LN.CNT 488
INCL INCLM: 623/001.150
INCL INCLS: 623/001.420
NCL NCLM: 623/001.150
NCLS: 623/001.420
IC [7]
 ICM A61F002-06
 IPCI A61F0002-06 [ICM, 7]
 IPCR A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-82 [N,C*];
 A61F0002-82 [N,A]; A61K0048-00 [I,C*]; A61K0048-00 [I,A];
 A61L0031-08 [I,C*]; A61L0031-10 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]

L22 ANSWER 32 OF 52 USPATFULL on STN
Full Text
AN 2005:38024 USPATFULL
TI Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
IN Averback, Paul, Beaconsfield, CANADA
Gemmell, Jack, Mississauga, CANADA
PA Nymox Pharmaceutical Corporation, St. Laurent, CANADA, H4M 2V2 (non-U.S. corporation)
PI US 20050032704 A1 20050210
 US 7408021 B2 20080805
AI US 2004-920313 A1 20041012 (10)
RLI Continuation of Ser. No. US 2002-294891, filed on 15 Nov 2002, PENDING
PRAI US 2001-331477P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 2571
INCL INCLM: 514/014.000
INCL INCLS: 530/326.000; 514/044.000; 536/023.500
NCL NCLM: 530/300.000; 514/014.000
NCLS: 514/044.000R; 530/326.000; 536/023.500
IC [7]
 ICM A61K038-10
 ICS A61K048-00
 IPCI A61K0038-10 [ICM, 7]; A61K0048-00 [ICS, 7]
 IPCI-2 A61K0038-00 [I,A]
 IPCR A61K0038-00 [I,C]; A61K0038-00 [I,A]; C07K0014-435 [I,C*];
 C07K0014-47 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 33 OF 52 USPATFULL on STN
Full Text
AN 2004:335619 USPATFULL
TI Selective inhibition of vascular smooth muscle cell proliferation
IN McEvoy, Leslie M., Mountain View, CA, UNITED STATES
Mann, Michael J., Palo Alto, CA, UNITED STATES
Parham, Christi, San Francisco, CA, UNITED STATES
Dzau, Victor J., Newton, MA, UNITED STATES
PI US 20040266712 A1 20041230
AI US 2004-819500 A1 20040406 (10)
PRAI US 2003-461626P 20030408 (60)
DT Utility
FS APPLICATION
LN.CNT 998
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000R
IC [7]
 ICM A61K048-00
 IPCI A61K0048-00 [ICM, 7]
 IPCR A61K0048-00 [I,C*]; A61K0048-00 [I,A]; C12N0015-11 [I,C*];
 C12N0015-11 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 34 OF 52 USPATFULL on STN
Full Text
AN 2004:308547 USPATFULL
TI Means and method for the treatment of coronary artery obstructions
IN Rischell, Robert E., Dayton, MD, UNITED STATES
Fischell, David R, Fair Haven, NJ, UNITED STATES

PI Fischell, Tim A., Richland, MI, UNITED STATES
US 20040243226 Al 20041202
AI US 2004-867410 Al 20040614 (10)
RLI Continuation of Ser. No. US 2001-969165, filed on 2 Oct 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 305
INCL INCLM: 623/001.430
NCL NCLM: 623/001.430
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]
IPCR A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61F0002-06 [I,C*];
A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-84 [I,A];
A61F0002-90 [N,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-519 [I,C*];
A61K0031-519 [I,A]; A61L0031-08 [I,C*]; A61L0031-10 [I,A];
A61L0031-14 [I,C*]; A61L0031-16 [I,A]; A61P0007-00 [I,C*];
A61P0007-02 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]

L22 ANSWER 35 OF 52 USPATFULL on STN

Full Text

AN 2004:281359 USPATFULL
TI Bioresorbable stent with beneficial agent reservoirs
IN Shanley, John F., Redwood City, CA, UNITED STATES
Litvack, Frank, Los Angeles, CA, UNITED STATES
Parker, Theodore L., Danville, CA, UNITED STATES
Diaz, Stephen Hunter, Palo Alto, CA, UNITED STATES
PI US 20040220660 Al 20041104
AI US 2004-822063 Al 20040408 (10)
RLI Continuation-in-part of Ser. No. US 2002-57414, filed on 25 Jan 2002,
PENDING Continuation-in-part of Ser. No. US 2004-777881, filed on 11 Feb
2004, PENDING Continuation-in-part of Ser. No. US 2003-447587, filed on
28 May 2003, PENDING
PRAI US 2001-266805P 20010205 (60)
US 2002-412489P 20020920 (60)
DT Utility
FS APPLICATION
LN.CNT 867
INCL INCLM: 623/001.160
INCLS: 623/001.420
NCL NCLM: 623/001.160
NCLS: 623/001.420
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-02 [N,C*];
A61F0002-02 [N,A]; A61F0002-06 [I,C*]; A61F0002-06 [I,A];
A61F0002-82 [I,C*]; A61F0002-90 [I,A]; A61L0031-14 [I,C*];
A61L0031-14 [I,A]; A61L0031-16 [I,A]

L22 ANSWER 36 OF 52 USPATFULL on STN

Full Text

AN 2004:191239 USPATFULL
TI Medical devices having porous layers and methods for making same
IN Lye, Whye-Kei, Charlottesville, VA, UNITED STATES
Looi, Karen, Charlottesville, VA, UNITED STATES
Reed, Michael L., Charlottesville, VA, UNITED STATES
PA SETAGON, INC., Charlottesville, VA (U.S. corporation)
PI US 20040148015 Al 20040729
US 7294409 B2 20071113
AI US 2003-713244 Al 20031113 (10)
PRAI US 2002-426106P 20021113 (60)
DT Utility
FS APPLICATION
LN.CNT 502
INCL INCLM: 623/001.150
NCL NCLM: 428/610.000; 623/001.150
NCLS: 216/075.000; 424/423.000; 623/001.390; 623/901.000
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]

IPCI-2 B22D0025-00 [I,A]; A61F0002-00 [I,A]; A61F0002-06 [I,A];
B44C0001-22 [I,A]
IPCR B22D0025-00 [I,C]; B22D0025-00 [I,A]; A61F0002-00 [I,C];
A61F0002-00 [I,A]; A61F0002-06 [I,C]; A61F0002-06 [I,A];
B44C0001-22 [I,C]; B44C0001-22 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 37 OF 52 USPATFULL on STN

Full Text

AN 2004:172641 USPATFULL
TI Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
IN Garvey, David S., Dover, MA, UNITED STATES
PA NitroMed, Inc., Bedford, MA, 01730 (U.S. corporation)
PI US 20040132805 A1 20040708
US 7138430 B2 20061121
AI US 2003-695644 A1 20031029 (10)
RLI Continuation of Ser. No. WO 2002-US13667, filed on 1 May 2002, PENDING
PRAI US 2001-287725P 20010502 (60)
DT Utility
FS APPLICATION
LN.CNT 3785
INCL INCLM: 514/456.000
INCLS: 549/398.000
NCL NCLM: 514/456.000
NCLS: 549/401.000; 549/407.000; 549/398.000
IC [7]
ICM C07D047-02
ICS A61K031-353
IPCI C07D047-02 [ICM,7]; A61K0031-353 [ICS,7]; A61K0031-352
[ICS,7,C*]
IPCI-2 A61K0031-352 [I,A]; C07D0311-04 [I,A]; C07D0311-00 [I,C*]
IPCR A61K0031-352 [I,C]; A61K0031-352 [I,A]; A61K0031-353 [I,A];
A61P0009-00 [I,C*]; A61P0009-00 [I,A]; C07D0311-00 [I,C];
C07D0311-04 [I,A]; C07D0311-22 [I,A]; C07D0311-58 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 38 OF 52 USPATFULL on STN

Full Text

AN 2004:38180 USPATFULL
TI Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
IN Marks, Andrew R., Larchmont, NY, UNITED STATES
Marx, Steven O., New York, NY, UNITED STATES
PI US 20040028716 A1 20040212
AI US 2003-460842 A1 20030612 (10)
PRAI US 2002-388760P 20020614 (60)
US 2002-388769P 20020617 (60)
DT Utility
FS APPLICATION
LN.CNT 800
INCL INCLM: 424/423.000
INCLS: 514/238.200
NCL NCLM: 424/423.000
NCLS: 514/238.200
IC [7]
ICM A61K031-537
ICS A61F002-00
IPCI A61K0031-537 [ICM,7]; A61F0002-00 [ICS,7]
IPCR A61K0031-4409 [I,C*]; A61K0031-4409 [I,A]; A61K0031-537 [I,C*];
A61K0031-537 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 39 OF 52 USPATFULL on STN

Full Text

AN 2003:289156 USPATFULL
TI Nitric oxide donors, compositions and methods of use related applications
IN Fang, Xinqin, Lexington, MA, UNITED STATES
Garvey, David S., Dover, MA, UNITED STATES
Gaston, Ricky D., Malden, MA, UNITED STATES
Lin, Chia-En, Burlington, MA, UNITED STATES

Ranatunga, Ramani R., Lexington, MA, UNITED STATES
Richardson, Stewart K., Tolland, CT, UNITED STATES
Wang, Tiansheng, Concord, MA, UNITED STATES
Wang, Weiheng, Bedford, MA, UNITED STATES
Wey, Shiow-Jyi, Woburn, MA, UNITED STATES
PI US 20030203915 Al 20031030
AI US 2003-407420 Al 20030407 (10)
PRAI US 2002-369873P 20020405 (60)
DT Utility
FS APPLICATION
LN.CNT 5615
INCL INCLM: 514/253.010
INCLS: 514/305.000; 514/275.000; 514/508.000; 514/484.000; 544/360.000;
544/322.000; 558/480.000
NCL NCLM: 514/253.010
NCLS: 514/275.000; 514/305.000; 514/484.000; 514/508.000; 544/322.000;
544/360.000; 558/480.000
IC [7]
ICM A61K031-496
ICS A61K031-505; A61K031-325; A61K031-215
IPCI A61K0031-496 [ICM,7]; A61K0031-505 [ICS,7]; A61K0031-325 [ICS,7];
A61K0031-215 [ICS,7]; A61K0031-21 [ICS,7,C*]
IPCR C07C0313-00 [I,C*]; C07C0313-36 [I,A]; C07D0211-00 [I,C*];
C07D0211-54 [I,A]; C07D0213-00 [I,C*]; C07D0213-74 [I,A];
C07D0217-00 [I,C*]; C07D0217-02 [I,A]; C07D0233-00 [I,C*];
C07D0233-96 [I,A]; C07D0239-00 [I,C*]; C07D0239-46 [I,A];
C07D0241-00 [I,C*]; C07D0241-08 [I,A]; C07D0241-24 [I,A];
C07D0295-00 [I,C*]; C07D0295-155 [I,A]; C07D0317-00 [I,C*];
C07D0317-22 [I,A]; C07D0453-00 [I,C*]; C07D0453-02 [I,A];
C07F0009-00 [I,C*]; C07F0009-38 [I,A]; C07F0009-40 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 40 OF 52 USPATFULL on STN

Full Text

AN 2003:238411 USPATFULL
TI Peptides effective in the treatment of tumors and other conditions
requiring the removal or destruction of cells
IN Averback, Paul, Quebec, CANADA
Gemmell, Jack, Mississauga, CANADA
PI US 20030166569 Al 20030904
US 7317077 B2 20080108
AI US 2002-294891 Al 20021115 (10)
PRAI US 2001-331477P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 2476
INCL INCLM: 514/014.000
INCLS: 530/326.000; 530/327.000
NCL NCLM: 530/300.000; 514/014.000
NCLS: 530/326.000; 530/327.000
IC [7]
ICM A61K038-10
ICS C07K007-08
IPCI A61K0038-10 [ICM,7]; C07K0007-08 [ICS,7]; C07K0007-00 [ICS,7,C*]
IPCI-2 A61K0038-00 [I,A]
IPCR A61K0038-00 [I,C]; A61K0038-00 [I,A]; C07K0014-435 [I,C*];
C07K0014-47 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 41 OF 52 USPATFULL on STN

Full Text

AN 2003:188929 USPATFULL
TI C3 exoenzyme-coated stents and uses thereof for treating and preventing
restenosis
IN Marx, Steven O., New York, NY, UNITED STATES
Marks, Andrew R., Larchmont, NY, UNITED STATES
PI US 20030130722 Al 20030710
US 7364586 B2 20080429
AI US 2002-326936 Al 20021220 (10)
PRAI US 2001-343030P 20011221 (60)
DT Utility
FS APPLICATION

LN.CNT 672
INCL INCLM: 623/001.150
NCL NCLM: 623/001.420; 623/001.150
NCLS: 623/001.480
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]
IPCI-2 A61F0002-06 [I,A]; A61L0033-00 [N,A]
IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61L0031-08 [I,C*];
A61L0031-10 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A];
A61L0033-00 [N,C]; A61L0033-00 [N,A]

L22 ANSWER 42 OF 52 USPATFULL on STN

Full Text

AN 2003:188435 USPATFULL
TI Prevention of atherosclerosis and restenosis
IN Chen, Wei-Jan, Taipei, CHINA
PI US 20030130228 A1 20030710
US 6939863 B2 20050906
AI US 2002-273057 A1 20021016 (10)
PRAI CN 2002-91113579 20020621
US 2002-345766P 20020104 (60)
DT Utility
FS APPLICATION
LN.CNT 1598
INCL INCLM: 514/050.000
NCL NCLM: 514/050.000
NCLS: 424/423.000
IC [7]
ICM A61K031-7072
IPCI A61K0031-7072 [ICM,7]; A61K0031-7042 [ICM,7,C*]
IPCI-2 A61N0043-04 [ICM,7]; A61K0031-70 [ICS,7]
IPCR A61K0031-7042 [I,C*]; A61K0031-7072 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 43 OF 52 USPATFULL on STN

Full Text

AN 2003:94019 USPATFULL
TI Means and method for the treatment of coronary artery obstructions
IN Fischell, Robert E., Dayton, MD, UNITED STATES
Fischell, David R., Fair Haven, NJ, UNITED STATES
Fischell, Tim A., Richland, MI, UNITED STATES
PI US 20030065382 A1 20030403
AI US 2001-969165 A1 20011002 (9)
DT Utility
FS APPLICATION
LN.CNT 325
INCL INCLM: 623/001.150
INCLS: 623/001.420
NCL NCLM: 623/001.150
NCLS: 623/001.420
IC [7]
ICM A61F002-06
IPCI A61F0002-06 [ICM,7]
IPCR A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61F0002-06 [I,C*];
A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-84 [I,A];
A61F0002-90 [N,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-519 [I,C*];
A61K0031-519 [I,A]; A61L0031-08 [I,C*]; A61L0031-10 [I,A];
A61L0031-14 [I,C*]; A61L0031-16 [I,A]; A61P0007-00 [I,C*];
A61P0007-02 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A]

L22 ANSWER 44 OF 52 USPATFULL on STN

Full Text

AN 2003:4519 USPATFULL
TI Medical device
IN Harnek, Jan, Malmo, SWEDEN
Zouka, Eftichia-Vassiliki, Malmo, SWEDEN
PI US 2003004565 A1 20030102
AI US 2002-169906 A1 20020711 (10)
WO 2001-SE126 20010124
PRAI SE 2000-3632 20000204

DT Utility
FS APPLICATION
LN.CNT 404
INCL INCLM: 623/001.150
NCL NCLM: 623/001.150
IC [7]
 ICM A61F002-06
 IPCI A61F0002-06 [ICM,7]
 IPCR A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61F0002-06 [N,C*];
 A61F0002-06 [N,A]; A61F0002-82 [I,C*]; A61F0002-82 [N,A];
 A61L0017-00 [I,C*]; A61L0017-00 [I,A];
 A61L0017-14 [I,A]; A61L0027-00 [I,C*]; A61L0027-34 [I,A];
 A61L0027-54 [I,A]; A61L0029-00 [I,C*]; A61L0029-00 [I,A];
 A61L0029-58 [I,A]; A61L0029-16 [I,A]; A61L0031-08 [I,C*];
 A61L0031-10 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A];
 A61L0033-00 [I,C*]; A61L0033-00 [I,A]; A61M0025-00 [I,C*];
 A61M0025-00 [I,A]; A61M0025-01 [I,C*]; A61M0025-01 [I,A]

L22 ANSWER 45 OF 52 USPATFULL on STN

Full Text

AN 2002:253824 USPATFULL
TI Multi layer radiation delivery balloon
IN Tam, Lisa A., Lake Forest, CA, United States
Trauthen, Brett A., Newport Beach, CA, United States
PA Endology, INC., Irvine, CA, United States (U.S. corporation)
PI US 6458069 B1 20021001
AI US 1999-382302 19990824 (9)
RLI Continuation-in-part of Ser. No. US 1999-253433, filed on 19 Feb 1999,
now abandoned Continuation-in-part of Ser. No. US 1999-256337, filed on
19 Feb 1999, now patented, Pat. No. US 6287249 Continuation-in-part of
Ser. No. US 1998-25921, filed on 19 Feb 1998, now abandoned
Continuation-in-part of Ser. No. US 382302 Continuation-in-part of Ser.
No. US 1998-40172, filed on 17 Mar 1998, now patented, Pat. No. US
6149574
DT Utility
FS GRANTED
LN.CNT 2079
INCL INCLM: 600/003.000
NCL NCLM: 600/003.000
NCLS: 977/949.000
IC [7]
 ICM A61N005-00
 IPCI A61N0005-00 [ICM,7]
 IPCR A61F0002-06 [N,C*]; A61F0002-06 [N,A]; A61F0002-82 [N,C*];
 A61F0002-82 [N,A]; A61K0009-16 [I,C*]; A61K0009-16 [I,A];
 A61K0051-12 [I,C*]; A61K0051-12 [I,A]; A61M0036-00 [I,C*];
 A61M0036-04 [I,A]; A61N0005-10 [I,C*]; A61N0005-10 [I,A];
 C04B0028-00 [I,C*]; C04B0028-02 [I,A]; G03C0005-02 [I,C*];
 G03C0005-02 [I,A]; G21G0004-00 [I,C*]; G21G0004-06 [I,A]
EXF 600/1-8

L22 ANSWER 46 OF 52 USPATFULL on STN

Full Text

AN 2002:105697 USPATFULL
TI Methods and compositions for the prevention and treatment of
atherosclerosis, restenosis and related disorders
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
PI US 20020054899 A1 20020509
 US 7182953 B2 20070227
AI US 2000-734460 A1 20001211 (9)
PRAI US 1999-170820P 19991215 (60)
DT Utility
FS APPLICATION
LN.CNT 1279
INCL INCLM: 424/422.000
NCL NCLM: 424/423.000; 424/422.000
IC [7]
 ICM A61F013-00
 IPCI A61F0013-00 [ICM,7]
 IPCI-2 A61F0002-02 [I,A]
 IPCR A61F0002-02 [I,C]; A61F0002-02 [I,A]; A61K0031-16 [I,C*];
 A61K0031-16 [I,A]; A61K0031-165 [I,C*]; A61K0031-165 [I,A];

A61K0031-185 [I,C*]; A61K0031-195 [I,A]; A61K0031-44 [I,C*];
A61K0031-44 [I,A]; A61K0031-445 [I,C*]; A61K0031-445 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 47 OF 52 USPATFULL on STN

Full Text

AN 2001:52110 USPATFULL
TI Vascular remodeling agent
IN Cote , Gilles , Ile-Des-Soeurs, Canada
Tardif, Jean-Claude, Laval, Canada
PA Quatro Scientific, Inc., Montreal, Canada (non-U.S. corporation)
PI US 6214887 B1 20010410
WO 9842327 19981001
AI US 1998-142507 19980908 (9)
WO 1998-CA269 19980323
19980908 PCT 371 date
19980908 PCT 102(e) date
PRAI US 1997-41456P 19970324 (60)
DT Utility
FS Granted
LN.CNT 848
INCL INCLM: 514/712.000
NCL NCLM: 514/712.000
IC [7]
ICM A61K031-10
IPCI A61K0031-10 [ICM,7]; A61K0031-095 [ICM,7,C*]
IPCR A61K0031-095 [I,C*]; A61K0031-10 [I,A]; A61L0031-08 [I,C*];
A61L0031-10 [I,A]

EXF 574/712

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 48 OF 52 USPATFULL on STN

Full Text

AN 1999:140974 USPATFULL
TI Vascular and endoluminal stents with iridium oxide coating
IN Alt, Eckhard, Eichendorffstrasse 52, Ottobrunn, Germany, Federal
Republic of 85521
Stotts, Lawrence J., 327 Linden La., Lake Jackson, TX, United States
77566
PI US 5980566 19991109
AI US 1998-59054 19980411 (9)
DT Utility
FS Granted
LN.CNT 538
INCL INCLM: 623/001.000
INCLS: 623/012.000; 604/198.000
NCL NCLM: 623/023.700
NCLS: 604/198.000; 623/023.710
IC [6]
ICM A61F002-06
IPCI A61F0002-06 [ICM,6]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-06 [I,C*];
A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-90 [I,A];
A61N0005-10 [N,C*]; A61N0005-10 [N,A]

EXF 623/1; 623/12; 604/198

L22 ANSWER 49 OF 52 USPAT2 on STN

Full Text

AN 2008:239635 USPAT2
TI C3 exoenzyme-coated stents and uses thereof for treating and preventing
restenosis
IN Marx, Steven O., New York, NY, UNITED STATES
Marks, Andrew R., Larchmont, NY, UNITED STATES
PA The Trustees of Columbia University in the City of New York, New York,
NY, UNITED STATES (U.S. corporation)
PI US 7662178 B2 20100216
AI US 2008-150695 20080429 (12)
RLI Continuation of Ser. No. US 2002-326936, filed on 20 Dec 2002, Pat. No.
US 7364586
PRAI US 2001-343030P 20011221 (60)
DT Utility
FS GRANTED

LN.CNT 917
 INCL INCLM: 623/001.420
 INCLS: 623/001.430
 NCL NCLM: 623/001.420
 NCLS: 623/001.430
 IC IPCI A61F0002-06 [I,A]
 IPCI-2 A61F0002-82 [I,A]; A61F0002-00 [I,A]
 IPCR A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61L0031-08 [I,C*];
 A61L0031-10 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
 EXF 623/1.15; 623/1.16; 623/1.17; 623/1.19; 623/1.2; 623/1.21; 623/1.22;
 623/1.42; 623/1.43; 623/1.44; 623/1.45; 623/1.46; 623/1.47; 623/1.48;
 623/1.49; 427/2.24; 427/2.25; 427/456

L22 ANSWER 50 OF 52 USPAT2 on STN
Full Text
 AN 2004:328442 USPAT2
 TI Drug/drug delivery systems for the prevention and treatment of vascular disease
 IN Falotico, Robert, Belle Mead, NJ, UNITED STATES
 Kopia, Gregory A., Hillsborough, NJ, UNITED STATES
 Llanos, Gerard H., Stewartsville, NJ, UNITED STATES
 PA Cordis Corporation, Miami Lakes, FL, UNITED STATES (U.S. corporation)
 PI US 7300662 B2 20071127
 AI US 2004-829074 20040421 (10)
 RLI Continuation-in-part of Ser. No. US 2001-850293, filed on 7 May 2001,
 ABANDONED Continuation-in-part of Ser. No. US 2000-575480, filed on 19
 May 2000, PENDING
 PRAI US 2001-263979P 20010125 (60)
 US 2001-263806P 20010124 (60)
 US 2001-262614P 20010118 (60)
 US 2001-262461P 20010118 (60)
 US 2000-204417P 20000512 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1993
 INCL INCLM: 424/424.000
 INCLS: 623/001.420; 623/001.450
 NCL NCLM: 424/424.000; 604/500.000
 NCLS: 623/001.420; 623/001.450
 IC IPCI A61N0001-30 [ICM,7]
 IPCI-2 A61F0002-00 [I,A]; A61F0002-06 [I,A]
 IPCR A61F0002-00 [I,C]; A61F0002-00 [I,A]; C07D0498-00 [I,C*];
 C07D0498-18 [I,A]; A61B0017-00 [I,C*]; A61B0017-00 [I,A];
 A61F0002-06 [I,C]; A61F0002-06 [I,A]; A61F0002-82 [I,C*];
 A61F0002-82 [I,A]; A61F0002-84 [I,A]; A61F0002-90 [I,A];
 A61K0031-365 [I,C*]; A61K0031-365 [I,A]; A61K0031-4353 [I,C*];
 A61K0031-436 [I,A]; A61K0031-726 [I,C*]; A61K0031-727 [I,A];
 A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0045-06 [I,A];
 A61K0047-30 [I,C*]; A61K0047-30 [I,A]; A61K0047-48 [I,C*];
 A61K0047-48 [I,A]; A61L0031-00 [I,C*]; A61L0031-00 [I,A];
 A61L0031-14 [I,C*]; A61L0031-16 [I,A]; A61M0031-00 [I,C*];
 A61M0031-00 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A];
 A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0009-10 [I,A];
 A61P0021-00 [I,C*]; A61P0021-00 [I,A]; A61P0029-00 [I,C*];
 A61P0029-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
 EXF 424/422-426; 623/1.42-1.48
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 51 OF 52 USPAT2 on STN
Full Text
 AN 2004:196448 USPAT2
 TI Hydrogel entrapping therapeutic agent and stent with coating comprising this
 IN Won, Chee-Youb, Livingston, NJ, UNITED STATES
 Zhang, Yeli, Somerville, NJ, UNITED STATES
 Chu, Chih-Chang, Ithaca, NY, UNITED STATES
 PA Cornell Research Foundation, Inc., Ithaca, NY, UNITED STATES (U.S. corporation)
 PI US 6905700 B2 20050614
 AI US 2004-762256 20040123 (10)
 RLI Continuation of Ser. No. US 143572, PENDING Division of Ser. No. US
 2002-143572, filed on 13 May 2002, Pat. No. US 6716445

Continuation-in-part of Ser. No. US 2000-531451, filed on 20 Mar 2000,
 Pat. No. US 6388047
 PRAI US 1999-128803P 19990412 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1106
 INCL INCLM: 424/426.000
 INCLS: 424/484.000; 424/486.000; 424/487.000; 424/488.000; 523/105.000;
 525/937.000; 602/048.000; 604/048.000
 NCL NCLM: 424/426.000; 424/423.000
 NCLS: 424/484.000; 424/486.000; 424/487.000; 424/488.000; 523/105.000;
 525/937.000; 602/048.000; 604/048.000
 IC [7]
 ICM A61K009-58
 ICS C08G063-08
 IPCI A61K0009-14 [ICM, 7]; A61F0002-00 [ICS, 7]
 IPCI-2 A61K0009-58 [ICM, 7]; A61K0009-52 [ICM, 7, C*]; C08G0063-08 [ICS, 7];
 C08G0063-00 [ICS, 7, C*]
 IPCR A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0047-36 [I,C*];
 A61K0047-36 [I,A]; C08B0037-00 [I,C*]; C08B0037-02 [I,A];
 C08G0018-00 [I,C*]; C08G0018-64 [I,A]; C08G0018-81 [I,A];
 C08L0005-00 [I,C*]; C08L0005-02 [I,A]; C08L0067-00 [I,C*];
 C08L0067-07 [I,A]
 EXF 424/426; 424/484; 424/486; 424/487; 424/488; 523/105; 525/937; 602/48;
 604/48
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 52 OF 52 USPAT2 on STN

Full Text

AN 2002:295551 USPAT2
 TI Stent device and method
 IN Alt, Eckhard, Eichendorffstr. 52, Ottobrunn, GERMANY, FEDERAL REPUBLIC
 OF 85521
 PI US 6613083 B2 20030902
 AI US 2001-847626 20010502 (9)
 DT Utility
 FS GRANTED
 LN.CNT 416
 INCL INCLM: 623/001.420
 NCL NCLM: 623/001.420
 IC [7]
 ICM A61F002-06
 IPCI A61F0002-06 [ICM, 7]
 IPCI-2 A61F0002-06 [ICM, 7]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-06 [I,C*];
 A61F0002-06 [I,A]; A61F0002-82 [I,C*]; A61F0002-82 [I,A];
 A61L0031-08 [I,C*]; A61L0031-08 [I,A]; A61L0031-14 [I,C*];
 A61L0031-14 [I,A]; A61L0031-16 [I,A]; A61L0033-00 [I,C*];
 A61L0033-00 [I,A]
 EXF 623/1.38; 623/1.39; 623/1.41; 623/1.42; 623/1.43; 623/1.44; 623/1.45;
 623/1.46; 623/1.47; 623/1.48; 623/23.7-23.76

=> log y
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
163.95	226.17

STN INTERNATIONAL LOGOFF AT 19:09:30 ON 17 FEB 2010